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”Considerate la vostra semenza: 
fatti non foste a viver come bruti, 
ma per seguir virtute e canoscenza" 
(Dante Alighieri) 
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Abstract 
Introduction. Congenital heart block (CHB) is a passively acquired autoimmune 
disease associated with transplacental transfer of maternal anti-Ro/SSA and/or 
anti-La/SSB antibodies mediating inflammation and subsequent fibrosis of the 
atrio-ventricular node in the fetal heart. Despite the long-established association of 
maternal antibodies in directly inducing CHB both with in vitro and in vivo studies, 
the pathogenic mechanisms involved remain unclear and identification of cross-
reactive targets of anti-Ro52 antibodies in the fetal heart is matter of debate. CHB 
occurs in 1–2% of anti-Ro/SSA antibody-positive pregnancies and has a 
recurrence rate of 12–20% in a subsequent pregnancy, suggesting that additional 
factors, such as genetic and environmental components may determine the 
outcome in terms of CHB development in autoantibody exposed fetuses. 
Objectives. This thesis is divided into two parts and investigates the pathogenic 
mechanism and the genetic association with CHB. The first study aims to identify 
cross-reactive targets of anti-Ro52/p200 antibodies by screening a library of 
peptides covering the whole human proteome and using monoclonal antibodies 
specific for the Ro52/p200 region and to confirm the reactivity at peptide level and 
on the whole antigen level. The second study aims to identify fetal susceptibility 
genes among the Human Leucocyte Antigen (HLA) locus in anti-Ro/SSA 
autoantibody-mediated CHB from DNA samples collected from a multi-centric 
European cohort of families in which children affected by CHB were born.  
Part I. A whole proteome microarray revealed 17 peptides to be significantly 
cross-reactive with a Ro52/p200 monoclonal antibody (Ab31) and two linear motifs 
(“YSDF” and “YSNF) were shared among these sequences. Among the targets, 
cross-reactivity was studied in detail for TG and GAK, for which reactivity was 
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showed both at the peptide and whole protein level with anti-p200 monoclonal 
antibodies and with sera from mothers whose children have CHB, suggesting that 
reactivity to these protein could represent a risk factor for development of CHB in 
the fetuses in anti-Ro/SSA-positive pregnancies. 
Part II. DNA from 636 individuals of 173 European families in which children 
affected from CHB were born (119 Swedish, 38 Finnish, 2 Norwegian and 14 
Italian families) was genotyped and imputation of HLA class I and HLA class II loci 
was performed. From the analysis, HLA-Cw*06, -DRB1*13, -DQA1*01 and -
DQB1*06 emerged as a protective alleles associated with CHB development, 
while HLA-DQA1*04 transmissions were associated with susceptibility. 
Furthermore, haplotype analysis revealed that the DRB1-DQA1-DQB1 13-01:03-
06:03 haplotype significantly associated with protection from CHB development, 
while DRB1-DQA1-DQB1 08-04:01-04:02 was significantly associated with CHB 
susceptibility. A parent-of-origin effect was seen for the following alleles: a lower 
maternal transmission to affected children was associated with Cw*06, while lower 
paternal transmission was observed for DQB1*06 and DRB1*07. With these 
findings, we propose that HLA typing in anti-Ro52-positive pregnancies might be a 
useful tool to assess the risk of CHB in the fetuses. 
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Riassunto 
Introduzione. Il blocco avtrio-ventricolare (BAV) congenito è una malattia 
autoimmune passiva associata al trasferimento transplacentare di anticorpi 
materni anti-Ro/SSA e/o anti-La/SSB, causando infiammazione e fibrosi del nodo 
atrio-ventricolare con successivo blocco cardiaco nel feto. Nonostante 
l’associazione diretta degli anticorpi materni nell'indurre il BAV sia da lungo nota, i 
meccanismi patogenetici coinvolti rimangono poco chiari e l'identificazione di 
bersagli di cross-reattività degli anticorpi anti-Ro52 nel cuore fetale è oggetto di 
dibattito. In aggiunta, Il BAV si verifica nel 1-2% delle gravidanze in cui sono 
presenti anticorpi anti-Ro/SSA e ha un tasso di ricorrenza del 12-20% nelle una 
successive gravidanze, suggerendo che fattori aggiuntivi, quali genetici e 
ambientali sono coinvolti nello sviluppo del BAV. 
Obiettivi. La prima parte della tesi riguarda uno studio che ha avuto lo scopo di 
identificare i bersagli di cross-reattività degli anticorpi anti-Ro52/p200 attraverso 
uno screening di una libreria peptidica coprente l'intero proteoma umano e 
l'utilizzo di anticorpi monoclonali specifici per la regione p200 della proteina Ro52. 
Ulteriore obiettivo è quello di confermare la reattività a livello di peptide e a quello 
di intero antigene. Il secondo studio ha lo scopo di studiare l’associazione genetica 
del locus “Human Leucocyte Antigen” (HLA) con il BAV in una coorte di famiglie 
europee in cui sono nati bambini con BAV. 
Parte I. Lo screening su base proteomica ha individuato 17 peptidi 
significativamente cross-reattivi con un anticorpo monoclonale specifico per la 
regione p200 (Ab31). Tra le 17 sequenze sono stati trovati due motivi lineari 
condivisi ("YSDF" e "YSNF). Tra i target positivamente legati dall’anticorpo Ab31, 
la cross-reattività è stata ulteriormente studiata per TG e GAK, per i quali la 
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reattività è stata dimostrata sia a livello peptidico, che e a livello di proteina intera, 
usando anticorpi monoclonali anti-p200 e sieri di madri i cui figli hanno il BAV. 
Reattività verso queste proteine potrebbe rappresentare un fattore di rischio 
maggiore per lo sviluppo del BAV nei feti in gravidanze positive per gli anticorpi 
anti-Ro/SSA. 
Parte II. Campioni di DNA provenienti da 636 individui da 173 famiglie europee in 
cui sono nati bambini affetti da BAV (119 svedesi, 38 finlandesi, 2 norvegese e 14 
italiane) è stato genotipizzato ed è stata eseguita l'imputazione dei loci HLA di 
classe I ed HLA di classe II. Dall'analisi è emerso che gli alleli HLA-Cw*06, -
DRB1*13, -DQA1*01 e -DQB1*06 conferiscono protezione dallo sviluppo BAV, 
mentre la trasmissione ai feti di HLA-DQA1*04 conferisce suscettibilità alla 
malattia. Inoltre, l'analisi ha rivelato che l’aplotipo DRB1-DQA1-DQB1 13-01:03-
06:03 è significativamente associato con la protezione dallo sviluppo BAV, mentre 
DRB1-DQA1-DQB1 08-04:01-04:02 è significativamente associato con 
suscettibilità al BAV. Infine, è’ stato osservato anche un effetto di origine parentale 
per questi alleli: -Cw*06 è associato una minore trasmissione materna ai bambini 
affetti, mentre DQB1*06 e DRB1*07 sono associati ad una inferiore trasmissione 
paterna. Con questi risultati, proponiamo che la genotipizzazione di questi alleli in 
gravidanze anti-Ro52-positive potrebbe essere un utile strumento per valutare il 
rischio di sviluppo del BAV nei feti. 
  
- 11 - 
 
1. Introduction 
1.1 Congenital heart block 
Congenital heart block (CHB) is a manifestation of neonatal lupus erythematosus 
(NLE), a passively acquired autoimmune condition caused by the transplacental 
transport of maternal autoantibodies (anti-SSA/Ro and anti-SSB/La) into the fetal 
circulation. Mothers usually present with systemic lupus erythematosus (SLE), 
Sjögren syndrome (SS), or undifferentiated connective tissue disease (UCTD), but 
may be also asymptomatic (1). Beside CHB, other manifestations of NLE are skin 
rash, hepatitis and cytopenias (2-5). Skin lesions or CHB occur in about 50% of 
NLE cases, but occurs concomittantly with CHB in only 10% of NLE cases (6). 
While CHB is a permanent condition, skin manifestations are transient and will 
disappear as maternal autoantibodies decrease in the child’s circulation to reach 
undetectable leves 6-8 months after birth (7). NLE occurs in 15-20% of infants 
born of mothers with SLE and anti-Ro/SSA antibodies (2). Liver involvement may 
be the only manifestation of NLE. It occurs in 25% of cases as reported in a 
prospective study (2). Liver involvement is usually transient and resolves within the 
first months of life (3). Cytopenia, as a manifestation of NLE, appears within the 
first week of life and tends to resolve by 2–4 weeks of age. It was found that 
neutropenia was much more commonly seen than thrombocytopenia, and that 
neutropenia occurs in up to 10–15% of children born to mothers with anti-Ro 
antibodies (2, 4).  
CHB, the most severe manifestation of NLE, is characterized by the delay or block 
of electrical conduction at the atrioventricular (AV) node that results in 
atrioventricular block (AVB) (8, 9). It occurs in a structurally normal heart and in 
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association of maternal anti-Ro/SSA and anti-La/SSB antibodies. CHB usually 
develops during the risk period between the 18th and the 24th weeks of pregnancy 
and is diagnosed in utero or within the neonatal period (0-27 days after birth) (10). 
According to the severity of the manifestation, AVB can be classified in three 
degrees. First-degree AVB is characterized by a prolonged interval between atrial 
and ventricular contraction, and can be visualized on an electrocardiogram (ECG) 
by a lengthened PR interval (11). In the second-degree AVB, some of the atrial 
impulses don’t reach the ventricles. Third-degree AVB, the most severe 
manifestation of CHB, is characterized by complete block of conduction of 
impulses through the AV node and dissociation between atrial and ventricular 
contraction, resulting in bradycardia. While I and II degree AVB are reversible, III 
degree AVB is irreversible and can lead to long-life pacemaker implantation or 
even death occurring in utero or perinatally (12, 13) and it is hypothesised that 
development of CHB from first to third degree is a progressive process (14). 
At the cellular and molecular level, CHB is characterized by deposition of immune 
complexes, signs of inflammation, calcification and fibrosis at the AV node in the 
fetal heart (15-17). 
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Figure 1. (A) The normal and the CHB-affected heart conduction system.  Electrical impulses are 
generated in the sino-atrial (SA) node and propagated from the atria to the ventricles via the 
atrioventricular (AV) node, before being conducted through the bundle of His to the bundle 
branches and the Purkinje fibers, and finally through the entire myocardium. (B) Electrocardiogram 
(ECG) showing the P wave and the QRS complex, which correspond to the atrial and ventricular 
depolarization, respectively. The PR interval is measured from the beginning of the P wave to the 
beginning of the QRS complex. (C) ECG showing a normal sinus rhythm, I-, II- and III-degree AV 
block. 
1.1.1 Epidemiology 
Complete CHB is considered a rare disease with a reported incidence of 1:15000 - 
1:20000 newborns in the general population. Recently, a population-based study 
which considered CHB cases in anti-Ro/SSA positive pregnancies and without 
structural heart diseases, reported that CHB II-III degree AVB occurs with an 
incidence of 1:23300. (18). The association of CHB with maternal autoantibodies 
directed to Ro/SSA and/or La/SSB is well verified (19-21). In women carrying anti-
Ro/SSA antibodies during pregnancy, the risk for fetuses to develop CHB is 1-2% 
A B 
C 
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in an anti-Ro/SSA positive pregnancy (22, 23) and the recurrence risk for the 
following pregnancies increases to 12-20% despite the persistence of 
autoantibodies (1, 24-26). The incidence of I and II degree AVB is still a matter of 
debate with contrasting data regarding the incidence of I-degree AVB ranging from 
3-14% in newborns from anti-Ro52 positive pregnancies (27-29), while about one 
third of fetuses of anti-Ro52 positive mothers show typical features of I-degree 
AVB in utero (14). Complete CHB is associated with a mortality rate of 15-20% (1, 
30-33), though a recent single-center prospective study reported a substantially 
lower mortality of CHB in anti-Ro/SSA positive pregnancies at 6% (18).  
 
1.2 Autoantigens and maternal autoantibodies in CHB 
Maternal autoantibodies directed to Ro/SSA and La/SSB antigens have been 
firmly associated with CHB (19-21). In the early ‘80s the presence of anti-Ro/SSA 
antibodies to ribonucleoprotein were demonstrated in sera from mothers who gave 
birth to infants with CHB (34-36). Maternal autoantibodies were also found in post-
mortem hearts of neonates deceased due to CHB (15, 17). Anti-Ro/SSA and anti-
La/SSB antibodies are common in the rheumatic diseases SS and SLE. In 
particular, in anti-Ro/SSA and anti-La/SSB antibodies are found in 40-95% of SS 
patients; while among SLE patients, 20-60% of them have anti-Ro/SSA and 10-
20% have anti-La/SSB in their serum (37). In the late ‘80s and early ‘90s the 
Ro/SSA autoantigen was shown to consist of two unrelated proteins, Ro52 and 
Ro60 (38-41).  
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1.2.1 The Ro/SSA and La/SSB antigens 
Ro52 
Ro52, is a 475 amino acid (aa) residues long protein with a molecular weight of 52 
kDa. It belongs to the tri-parted motif (TRIM) family of proteins (42). It is composed 
of a RING and a B-box motifs, followed by a coiled-coil (CC) domain, which 
contains a leucine zipper motif, and a B30.2 (or PRYSPRY) region in the C-
terminal end (Figure 2) (43). 
Figure 2. The structural domains of Ro52 (Oke et al., Journal of Autoimmunity 2012). The RING, 
B-box and coiled-coil domain constitute the TRIM motif. The coiled-coil domain contains a leucine 
zipper motif and the C-terminal of the protein include a B30.2 (PRYSPRY) domain. 
As a TRIM protein, Ro52 is also denoted TRIM21, and Trim21 is the official name 
of the Ro52 gene (42), which is mapped along 8.8 Kb of chromosome 11 and 
consists of 7 exons. The gene is expressed mainly in immune cells 
(http://biogps.org) (44, 45) 
Many of the proteins in the TRIM family play an important role in innate immunity 
and anti-viral responses (46, 47), but also in regulating immune responses by 
targeting key molecules involved in proliferation, survival or death of cells (48).  
Like several other TRIM proteins, Ro52 has E3 ligase activity and acts in the 
process of ubiquitination (49). Ubiquitination is a process of post-translational 
modification of proteins, conserved in eukaryotic cells and it is used to control 
biological processes such as protein degradation, trafficking and activation (50-
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52). The process of ubiquitination is a complex three-step pathway requiring 
energy (ATP). The first step includes binding and activation of the ubiquitin 
molecule by a ubiquitin activating enzyme (E1). The activated ubiquitin molecule is 
then transferred to a ubiquitin conjugating enzyme (E2). In the last step, a ubiquitin 
ligase (E3) mediates the transfer of the ubiquitin to from the E2 to a lysine residue 
of the target protein (Fig. 3) (51, 52). Ubiquitinated proteins are commonly targeted 
to the proteasome, where they are degraded. Proteins can be modified by 
ubiquitination in three different ways: mono-ubiquitination, where a single ubiquitin 
molecule is attached to the target protein; multi-ubiquitination, where several 
single ubiquitin moieties are covalently bound to separate lysine residues on the 
target protein; and poly-ubiquitination, where a chain of ubiquitin molecules is 
added to a single lysine residue on the target.  
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It has been demonstrated that Ro52 may regulate both cytoplasmic and nuclear 
substrates via ubiquitination, interacting either with the E2s UBE2D1 and UBE2E1 
located in the cell cytoplasm and nucleus, respectively (49, 53). Targets of 
ubiquitination mediated by Ro52 include Interferon regulatory transcription factor 
(IRF) 3, IRF5, IRF7 and IRF8 (45, 49, 54-56), diminishing their activity (56). Ro52, 
as all the TRIM family proteins, is a critical regulator of innate immune response 
specifically in antiviral immunity (57, 58). The interferon (IFN) and NF-κB are the 
Figure 3. The process and diverse outcomes of ubiquitination. (A) Crystal structure of Ubiquitin 
showing seven conserved lysine and C-terminal di-glycine motif. (B) Ubiquitination of target protein 
involves the sequential action of three enzymes: E1, E2 and E3. (C) Different forms of protein 
ubiquitination and their fate. Proteins can be mono-ubiquitinated with a single Ub, 
multi-ubiquitinated or poly-ubiquitinated. Poly-ubiquitination can be of different types depending on 
the Ub lysine residue which is targetted for Ub chain elongation. The different fates of the modified 
proteins have been shown in the figure. (figure from Tomar et al., Bio Cell 2015) 
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critical pathways in the regulation of innate immune response during viral infection, 
regulating the expression of various cytokines and other immunity-related genes 
(52, 59). The stimulation of cells with IFN leads to the accumulation of Ro52 in the 
nucleus (60) which ubiquitinates IRF8 and enhances cytokine expression, 
specifically type I IFN (61, 62). It was also shown that Ro52 is involved in 
regulation of NF-κB, inducing mono-ubiquitination and subsequent autophagic 
degradation of IKKβ, a positive regulator of NF-κB (63). Hence, degradation of 
IKKβ suppresses NF-κB activity. 
Ro52 function has been studied also in Ro52-deficient mice (45). A distinct role for 
Ro52 in Th17-related autoimmunity was demonstrated with enhanced production 
of proinflammatory cytokines that are regulated by the IRF transcription factors, 
including cytokines involved in the Th17 pathway (IL-6, IL-12/IL-23p40, and IL-17). 
Disruption of the IL-23/Th17 pathway in the Ro52-deficient mice by deletion of 
p19, a subcomponent of the heterodimeric IL-23 cytokine, provided complete 
protection from the skin inflammation and systemic autoimmunity, revealing the 
importance of Ro52 as a negative regulator of proinflammatory cytokine 
production (45).  
Ro52 is involved also in the regulation of the cell cycle and apoptotic process but 
discordant findings have been present. Overexpression of Ro52 in stably 
transfected B cells leads to decreased proliferation and increased sensitivity to 
CD40-mediated cell death, (49). In contrast to these findings, it was described that 
knock-down of Ro52 leads to impaired progression of the cell cycle caused by 
accumulated p27 and inability of cell to enter S-phase (64). These observations, 
though, are all made in in vitro systems using different cells and experimental 
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conditions. More investigations are thus needed to allow a better understanding of 
the role for Ro52 in the regulation of the cell cycle and apoptotic process. 
Ro60 
60 kDa-Ro60 is an RNA-binding protein (65) encoded by the gene TROVE2 in 
humans. The protein is conserved from Caenorhabditis. elegans to all vertebrates 
and found also in the green algae Chlamydomonas, several eubacteria and one 
mycobacteriophage (66). It is ubiquitously expressed and shaped like a doughnut 
with an inner hole. In vertebrate cells, Ro60 is normally complexed with small 
noncoding RNAs, known as YRNAs. It has been shown that the protein also binds 
misfolded, non-coding RNAs that are eventually degraded (67-69) and likely 
functions in a quality control pathway by which incorrectly folded or defective non-
coding RNAs are targeted for degradation (65, 66). In addition, studies of Ro60 in 
both mammalian cells and bacteria have revealed that the protein is important for 
cell survival after ultraviolet irradiation (69, 70). Recently it was shown that Ro60 
also binds repetitive transposons called Alu retroelements, leading to an aberrant 
Toll-like receptor (TLR) signalling which is TLR7- and TLR8-dependent (71, 72). 
Moreover, Alu transcripts were induced by type I IFN and stimulated 
proinflammatory cytokine secretion by human peripheral blood cells and Ro60 
deletion resulted in enhanced expression of Alu RNAs and IFN-regulated genes.  
La 
The SSB/La antigen is a single 48 kDa nuclear phosphoprotein encoded by SSB 
gene in humans. Expressed ubiquitously in eukariotic cells (73, 74), the La protein 
associates with the 3’ of many newly sinthesized RNA plymerase III transcripts, 
including pre-tRNA and pre-5S rRNA and other small RNA. This binding prevents 
this RNA precursor from digestion by exonucleases and it is important for their 
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maturation (74-77). Moreover it has been observed that in adenovirus- or Epstein-
Barr-infected cells, La can bind viral-encoded RNAs and therefore may be 
involved in virus replication (76, 78, 79).  
1.2.2 Anti-SSA/Ro and anti-SSB/La antibodies 
CHB appears to be more specifically linked to the presence of maternal anti-
Ro/SSA and anti-La/SSB antibodies rather than to maternal diagnosis, as the 
mother of an affected child may be also asymptomatic (13, 30, 80).  
Regarding the Ro/SSA autoantigen, older studies did not distinguished between 
Ro52- and Ro60-specific antibodies (38, 40, 41). Subsequent studies regarding 
the association of maternal antibodies with CHB tried to determine the serum 
profile of mothers of affected children in relation to the three components Ro52, 
Ro60 and La and are described below.  
Anti-Ro52/p200 antibodies 
Anti-Ro52 antibodies are the most common specificity in primary SS where can be 
found in 66.7% of the patients (81). Co-uccurrence of these antibodies with anti-
Ro60 is observed in 52.1% of patients with primary SS, while anti-Ro52 together 
with anti-La are are present at the same time in 49% of these patients. In SLE, as 
well as systemic sclerosis and autoimmune myositis patients, anti-Ro52 antibodies 
are detected in one third of patients (62, 81). In CHB, instead, most studies aiming 
to screen for a specific maternal antibody profile have found an almost universal 
presence of antibodies targeting the Ro52 protein (12, 20-22, 82-89). More 
recently this finding was confirmed in a Swedish cohort of 193 mothers of children 
with CHB, where 95% of cases of antibody-related CHB were positive for anti-
Ro52 (90).  
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Systematic analyses have been undertaken to identify the subpopulation and 
specificity of anti-Ro52 antibodies that correlate with congenital heart block and it 
was revealed that a major antigenic part resides in the central part of Ro52, inside 
the leucine zipper structure in the coiled-coil domain (Figure 1) (21, 91-95). 
Epitope mapping using overlapping peptides covering this domain revealed a 
significant association of autoantibodies against amino acid sequence 200-239 
(p200) of the Ro52 protein with a higher risk of developing CHB (21, 87, 89, 96). 
Another study based on structurally derived mutations in different p200 syntetic 
peptides and circular dichroism allowed a better definition of the borders of the 
antigenic p200 region and revealed that binding of human monoclonal anti-Ro52 
antibodies to p200 is dependent on a partly α-helical fold within the leucine zipper 
of p200 (96). 
In a prospective study of 25 anti-Ro52-positive pregnant women, maternal 
antibodies anti-p200 were found to correlate to longer AV time intervals in fetuses 
(87). In addition, in a retrospectively collected Swedish cohort of mothers of 
children with CHB, 60% of anti-Ro52-positive sera also bound p200 (90). The 
association of anti-p200 antibodies with CHB outcome was also re-confirmed 
recently by an Italian multi-center study (97). In particular anti-p200 antibodies 
were significantly more frequently positive in mothers of children with CHB child 
than in women with healthy children (81.0% vs 59.1%, respectevely). Given the 
low risk of developing CHB in anti-Ro/SSA positive women, it has been suggested 
that also the levels of maternal anti-Ro52 antibodies are important in prediction of 
the pregnancy outcome (21). This hypothesis was corroborated also by an another 
group, which found that cardiac complication is associated with moderate or high 
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levels of maternal anti-Ro/SSA, but not with low levels in a group of children born 
by anti-Ro-positive mothers (98).  
Also the specific interaction between anti-Ro52 antibodies and the corresponding 
antigen has been investigated (99). It was found that anti-Ro52-positive patient 
sera inhibited the E3 activity of Ro52 in ubiquitination assays and that anti-Ro52 
autoantibodies inhibited the E3 ligase activity of Ro52 by sterically blocking the 
E2/E3 interaction between Ro52 and UBE2E1 (99).  
Anti-Ro60 
Anti-Ro60 antibodies are mostly present together with anti-Ro52 antibodies and 
many studies still rely on clinical assays which don’t distinguish between Ro52 and 
Ro60 to investigate the presence of anti-Ro antibodies in maternal sera. It is, 
therefore, difficult to assess the individual clinical value of anti-Ro60 in the 
development of CHB. However, in a study by Salomonsson and colleagues, anti-
Ro60 antibodies were found in 63% of antibodies-positive CHB pregnancy (90), 
but this antibody occurred in anti-Ro52-negative mothers only in 3% of cases. 
Anti-Ro60 antibodies have been suggested to have a minor role in predicting the 
fetal clinical outcome in anti-Ro and anti-La antibody–positive mothers (21, 85, 
100), although an association also between these autoantibodies and the 
incidence of CHB has been demonstrated (85, 101). 
Anti-La antibodies 
The association of anti-La antibodies to CHB is still matter of discussion. The level 
of antibodies to the La protein has been found to be higher in mothers of children 
developing cutaneous lupus rather than heart block (3, 85, 98). However, another 
study suggested that the presence of anti-La antibodies increases the risk of CHB 
(101). As for anti-Ro60 antibodies, also anti-La antibodies have been considered 
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less associated to CHB than anti-Ro52 (50, 55, 56). Anti-La antibodies were found 
in 59% of antibody-positive women with a CHB baby (90). The current general 
opinion is that although CHB may develop independently of maternal antibodies 
against Ro60 and La, their presence might be able to amplify the immunological 
response that leads to the AV block (102). 
1.2.3 Other autoantibodies 
In addition to antibodies directed to the Ro and La proteins, several other targets 
have been investigated for being associated with development of CHB. Antibodies 
to calreticulin, a protein involved in calcium storage in myocytes, have been found 
more frequently in sera from mothers of children with CHB than in sera of mothers 
of healthy children (103). Antibodies recognizing the neonatal heart muscarinic 
acetylcholine receptor (mAChR) have been thought to have a functional role in the 
disease supported by binding, and biological effects in in vitro studies (104, 105). 
Antibodies to a cleavage product of α-fodrin has been suggested as an additional 
serologic marker for CHB, in addition to being commonly found in patients with SS 
(106). Another suggested antibody specificity associated with congenital heart 
block is antibodies to p57, which was identified in a child with the disease (86, 
107). All these studies, however, were not able to provide a strong association of 
the proposed antibodies with the involvement in development of CHB (80). 
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1.3 Pathogenesis of CHB 
1.3.1 Evidence of a pathogenic role of maternal anti-Ro/SSA and 
anti-La/SSB antibodies 
Several experimental studies, both in vitro and in vivo, have provided direct 
evidence for a pathogenic role of maternal anti-Ro/SSA and anti-La/SSB and 
especially anti-Ro52 antibodies in the development of CHB. The first 
demonstration of this link was provided in the ‘80s by several groups which 
showed the presence of anti-Ro/SSA antibodies in the cardiac tissue of fetuses 
with CHB, together with deposition of complement, fibrosis and calcification (15-
17, 108, 109). Later, in in vitro studies, perfusion of rat or human hearts with the 
Langendorff technique with maternal IgG containing anti-Ro/SSA and anti-La/SSB 
antibodies was shown to induce bradycardia and complete AVB (110, 111). The 
same effect was gained using affinity-purified anti-Ro52 antibodies, showing a 
direct pathogenic role of maternal autoantibodies specific for the Ro52 antigen.  
In vivo studies provided more evidence of the pathogenic role of anti-Ro/SSA and 
anti-La/SSB antibodies based on models of active immunization of rats, mice or 
rabbits females before gestation or passive transfer of antibodies in pregnant 
animals. 
Among immunization studies, immunizing BALB/c mice with Ro60 or La, led to 
development of I-degree AVB in 19% and 7% of the offspring, respectively (112) 
and similar results were observed in C3H/HEJ mice (113). Instead, in two different 
studies immunization of the same model of BALB/c mice with human Ro52 led to 
I-degree AVB and to II/III-degree AVB in 9-25% and in 3.5-10% of offspring, 
respectively (110, 112). In rats, immunization with human Ro52 induced I-degree 
AVB in 10-45% of pups, depending on the strain (114). A pathogenic role of 
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antibodies specific for the p200 peptide has also been shown. After immunization 
of Dark Agouti (DA) rats with p200 peptide 19% of offspring developed I-degree 
AVB (87). 
Immunization-based experiments present an intrinsic variability that rely on the 
immune response of each immunized animal, dependent also on factors like 
genetic background, age and immunization process. In the context of CHB it was 
shown that induction of the disease depends on the antibody response initiated in 
the mother and that maternal major histocompatibility complex (MHC) is crucial in 
the generation of pathogenic antibodies in CHB (114). Injecting antibodies directly 
into the females during gestation, instead, allows to overcome these problems and 
provided advantages in knowing the specificity and the amount of antibodies 
transferred in the animals. It was shown that transfer of affinity-purified anti-
Ro/SSA and anti-La/SSB antibodies from mothers of children with CHB into 
pregnant females BALB/c mice induced I-degree AVB in 47-90% of the offspring, 
depending on the day of gestation at which the injection was performed (115). 
Instead, transfer of monoclonal antibodies specific for the p200 region of Ro52 in 
rats induced AV block in 100% of offspring but injection of antibodies targeting 
other domains of Ro52 did not (116). In addition, anti-p200 antibodies were shown 
to disturb calcium homeostasis in cultured neonatal cardiomyocytes, supporting a 
pathogenic role for anti-p200 antibodies in CHB (116). 
1.3.2 Pathogenic mechanism 
Despite the big achievement in showing that anti-Ro/SSA and anti-La/SSB have a 
direct pathogenic role in CHB, the mechanism by which they induce the disease is 
still not known. The intracellular localization of Ro52, Ro60 and La proteins and 
the lack of evidence that maternal antibodies can cross the sarcolemma of a 
- 26 - 
 
normal cardiomyocyte and bind to the specific antigens are the biggest obstacle in 
elucidating the molecular mechanism of CHB induction. Based on this fact two 
hypotheses of the pathogenic mechanisms, not mutually exclusive and each 
supported with experimental data, have been proposed: the “apoptosis 
hypothesis” and the “cross-reactivity hypothesis”.  
The apoptosis hypothesis  
According to the apoptosis hypothesis, the maternal autoantibodies gain access to 
their target antigens when they are exposed on the surface of apoptotic cells. 
Supporting this idea were the observations that Ro60 was found to be displaced to 
the surface blebs in apoptotic keratinocytes (117) and, then, that Ro60 was also 
present on the surface of early apoptotic cardiomyocytes (102, 118), and therefore 
exposed to binding by anti-Ro60 antibodies. Conversely, Ro52 was found to be 
exposed only after plasma membrane breaking in necrotic cells (102) and was 
bound by anti-Ro52 monoclonal antibodies to a lesser extent than anti-Ro60 and 
anti-La did (119). This discovery and the observation of exaggerated apoptosis 
and infiltrating macrophages in the heart of fetuses dying of CHB (109) supported 
the hypothesis that maternal anti-Ro60 may bind to apoptotic cardiac cells during 
apoptosis normally occurring in developing fetal hearts and so deviate the removal 
of apoptotic debris from a non-inflammatory pathway to their ingulfment by 
macrophages by opsonization. Subsequent activation of the phagocytic cells may 
lead to production of pro-inflammatory and pro-fibrotic cytokines, recruitment of 
leukocytes and complement components, and establishment of an inflammatory 
reaction that will eventually irreversibly damage the targeted tissue (109, 120). 
Subsequent in vitro studies showed that opsonized cardiomyocytes can activate 
phagocytic cells to produce pro-inflammatory and pro-fibrotic cytokines (120-122). 
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It is of note, though, that these experiments were performed in ventricular 
myocytes, not in conduction system myocytes such as AV node myocytes, and the 
correlation of these findings with the AV conduction abnormalities seen in CHB is 
not straightforward. According to these in vitro studies anti-Ro60 would first bind to 
apoptotic cells and later anti-Ro52 to necrotic cells, leading to establishment of 
inflammation and fibrosis in the fetal heart. These findings are, however, not in 
accordance with the in vitro and in vivo observation that anti-Ro52 are the most 
common in mothers of children with CHB (12, 20, 90) and that they have been 
shown to induce AVB in several animal models of CHB (110, 112, 114, 116). 
The cross-reactivity hypothesis  
Several studies have shown arrythmogenic effects of anti-Ro52 antibodies either 
with Langendorff-perfused hearts (110, 111) and with transfer of monoclonal 
antibodies anti-p200 in pregnant rats (116). Calcium homeostasis disturbance was 
also shown in cultured neonatal cardiomyocytes after adding anti-p200 antibodies 
(116). These data, together with the intracellular localization of Ro52 in live cells 
and the fact that Ro52 is predominantly expressed in immune cells (44, 45) and 
functions as a ubiquitin E3 ligase (49), support the idea that anti-Ro52 antibodies 
may mediate their pathogenic effect on the fetal hearts by cross-reacting with 
another targets available in the extracellular space. This targeted molecules might 
be involved in the control of electric signal or conduction and cross-reactivity might 
interfere with normal cardiac function. 
Several targets have been proposed as cross-reactive targets and a list of studies 
is reported below (Table 1). The 5-HT4 serotoninergic receptor (5-HT4R) was 
suggested by Eftekhari and colleagues (123) as a putative cross-reactive target. In 
this study they found that antibodies specific for peptide 365-382 of Ro52 
- 28 - 
 
recognized residues 165-185 of the cardiac 5-HT4R (123) and that affinity-purified 
5-HT4R antibodies could antagonize the serotonin-induced calcium channel 
activation in atrial cells (124). However, mouse pups born to females immunized 
with Ro52 peptides cross-reacting with anti-5-HT4R antibodies did not develop 
any sign of AVB or any other cardiac dysfunction (124). Additionally, others 
couldn’t reproduce this data and were not able to confirm the reactivity to the 
specific epitope of 5-HT4R in any of 116 sera from mothers with affected children 
(125), leading to discordant results about this putative target (126).  
Other than 5-HT4R, L- and T-type calcium channels were suggested as potential 
cross-reactive targets, supported by the observation that inhibition or blockade of 
this channel lead to AV block similar to conduction abnormalities seen in CHB. 
Specifically, the L-Type calcium channels subunits Cav1.2 (α1C) and Cav1.3 
(α1D) are essential for AV node electro genesis and cardiac excitation-contraction 
coupling, with Cav1.2 crucial for cardiac contractility and Cav1.3 more important 
for atrial sinus pacemaker activity and signal conduction (127-129). Cav1.3, 
moreover, was also was shown to be expressed in human fetal heart (130).  
 In vitro experiments have shown that IgG purified from mothers with CHB-positive 
pregnancy could inhibit L-Type calcium currents in ventricular myocytes, sino-atrial 
and AV node cells as well as in exogenous expression systems (111, 130-134). 
Cross-reactivity of anti-Ro/SSA and anti-La/SSB antibodies with the Cav1.2 and 
Cav1.3 calcium channels has been proved (130, 133). Maternal antibodies have 
been proposed to induce, after cross-reactivity, calcium channel internalization 
and degradation with subsequent inefficient signal conduction, insufficient 
excitation-contraction coupling and reduction of cardiac contractile function (132). 
Supporting this hypothesis, mouse pups transgenic for Cav1.2 developed AV 
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block and sinus bradycardia at a lower frequency than non-transgenic littermates 
after in utero exposure to anti-Ro/SSA and anti-La/SSB antibodies in an 
immunization model (135). In addition, mouse pups in which the Cav1.3 subunit of 
the L-type calcium channel has been genetically knocked out exhibit first-degree 
AV block, albeit at a low frequency, and the occurrence of AV block is increased 
following immunization of females with the Ro and La protein before gestation 
(135). This study, however, doesn’t show the specific interaction of maternal 
autoantibodies with the calcium channels. More recently, Strandberg and 
colleagues (136) found that sera from mothers with CHB affected children were 
able to bind the T-Type calcium channel subunit Cav3.1 (α1G) and to a lesser 
extent with Cav3.2 (α1H) and decrease of T-type calcium channel currents was 
seen in mouse sino-atrial node cells.  
Cross-reactivity to α-Enolase, a glycolytic enzyme expressed on the membranes 
of several hematopoietic, epithelial, and endothelial cells, has been proposed as 
the target of anti-p200 monoclonal antibodies after a screening of a neonatal rat 
heart expression library (137). However, only a small proportion of anti-Ro52 
positive sera from women with CHB pregnancy were also positive for this target, 
indicating that these antibodies may represent only a subset of mothers at risk 
(138). In conclusion, so far, none of the suggested cross-reactivity targets has 
been confirmed convincingly and showed to be a major target of cross-reaction. 
Moreover, even if previous studies showed that autoantibodies specific for p200 
region interact with cardiomyocytes and disturb calcium homeostasis (87, 116), 
their cross-reactivity has not been investigate thoroughly.  
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 Taking together the results of these studies, an attempt of merging together 
the apoptosis and cross-reactivity hypotheses has been made in order to better 
explain the molecular mechanism leading to CHB (139). The current opinion 
proposes a scenario in which, after crossing placenta, anti-Ro52 antibodies may 
cross-react with one or several molecules such as calcium channels on the 
surface of fetal cardiac cells, inducing disturbancies in calcium homeostasis. 
Prolonged exposure to maternal autoantibodies may then lead to increased 
cardiomyocytes apoptosis, followed by exposure of Ro52, Ro60 and La antigens. 
The consequent autoantibodies binding allows establishment and amplification of 
inflammatory reaction as described for the apoptosis hypothesis with eventual 
fibrosis and calcification in the AV nodes and establishment of complete CHB, as 
depicted in Figure 4. 
 
Figure 4. Schematic representation of events in the pathogenesis of congenital heart block. 
(Image from: (Ambrosi et al., Exp Cell Res. 2014;325:2-9) 
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Cross-reactivity 
target 
Antibodies/method Major finding Reference 
5-HT4R 
Sera from SLE patients anti-Ro52- 
positive  
cross-reaction with second extracellular 
loop of  5-HT4R 
Eftekhari et 
al., 2000 
(123) 
5-HT4R 
Immunization of mice with 5-HT4R 
peptides (a); or Ro52 (b) 
Mice developed bradycardia, AVB I- and 
II-degree (a); not developed any 
symptomps of CHB (b) 
Eftekhari et 
al., 2001 
(124) 
5-HT4R 
Sera from mothers with CHB 
pregnancy 
None cross-reacted with 5-HT4R 
Buyon et al., 
2002 (125) 
5-HT4R 
Sera anti-Ro/La positive from 
mothers with/without CHB children 
and healty controls 
Reactivity to 5-HT4R was found in 16% 
of mothers with CHB 
Kamel et al., 
2005 (126) 
L-Type calcium 
channels 
Perfusion of rat hearts with  IgG from 
anti-Ro/SSA-positive sera 
Inhibition of whole cell L-Type calcium 
current I(Ca) 
Boutjdir et 
al., 1998 
(111) 
L-Type calcium 
channels  subunit 
α1D 
Effect of  IgG containing anti-Ro/La 
on I(Ca) in heterologous expression 
systems  
IgG binds directly to α1D Ca channel 
protein and inhibited I(Ca) 
Qu et al., 
2005 (130) 
L-Type calcium 
channels  subunit 
α1C 
Effect of  IgG containing anti-Ro/La 
on I(Ca) in heterologous expression 
system 
IgG binds directly to α1C Ca channel 
protein and inhibited I(Ca) 
Xiao et al., 
2001 (131) 
L-Type calcium 
channels 
Immunization of pregnant rabbits 
with Ro52 
Conduction defects and down-regulation 
of L-Type calcium channels in newborns. 
Inhibition of I(Ca) through IgG from 
immunized animals 
Xiao et al., 
2001 (132) 
L-Type calcium 
channels  subunit 
α1C 
Effect of  IgG containing anti-Ro/La 
on I(Ca) in human fetal Purkinje 
myocytes and in heterologous 
expression system 
IgG bound α1C and inhibites I(Ca) in 
both systems 
Qu et al., 
2001 (133) 
L-Type calcium 
channels  subunit 
α1D 
Sera anti-Ro/La positive from 
mothers with/without CHB children 
and healty controls. Effect of  IgG on 
I(Ca) in heterologous expression 
system 
14% sera from mothers with CHB bound 
extracellular loop of domain I S5-S6 
region of α1D and  reduction of I(Ca)  
Karnabi et 
al., 2010 
(134) 
L-Type calcium 
channels 
Overexpression of L-Type calcium 
channels in Ro/La-immunized 
pregnant mice 
Rescueing of AVB inMice pups with 
overexpressed L-Type calcium channels. 
interaction of maternal autoantibodies 
with the target not shown 
Karnabi et 
al., 2011 
(135) 
T-Type calcium 
channel subunit 
α1G and α1H 
Sera from mothers with CHB baby 
Binding to α1G and to a lesser extent to 
α1H.  Decreased I(Ca) in mouse sino-
atrial node 
Strandberg 
et al., 2013 
(136) 
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α-Enolase Anti-p200 monoclonal antibodies 
Reactivity shown in ELISA and 
westernblot 
Ambrosi et 
al., 2007 
(137) 
α-Enolase 
anti-Ro52 positive sera from women 
with CHB pregnancy 
7% of sera positive for α-Enolase 
reactivity. Preincubation with Ro52 did 
not inhibit anti-α-enolase reactivity. 
Llanos et al., 
2009 (138) 
 
 
 
1.4 Risk factors for CHB development  
As the risk for CHB in anti-Ro/SSA- and/ anti-La/SSB-positive women is only 1-2% 
(22, 23) and the recurrence rate in the following pregnancies is 12-20%, despite 
the persistence of maternal autoantibodies (1, 24-26), it is clear that the sole 
presence of these antibodies is not sufficient to provoke CHB. This fact indicates 
that additional factors, maternal and fetal, genetic and enviromental, may be 
necessary for development of CHB in an autoantibody exposed fetus (Figure 5). 
1.4.1 Genetic risk factors 
Completion of the sequencing of the human genome in the early 2000s and a big 
improvement in the technology of genotyping and statistical analysis was the basis 
for researchers to discover that autoimmune diseases have a consistent genetic 
component, with the Human Leucocyte Antigen locus (HLA) being the most 
significantly associated with rheumatic disorders (140, 141). Regarding CHB, 
maternal and fetal genetic susceptibility has been investigated firstly by a Finnish 
group (142-145), which suggested that the disease-associated HLA alleles were 
potentially linked, in mothers, with the specificity and/or the levels of 
autoantibodies, as well as with the competence of immune system to fight 
infections and, in children, with the specificity of antigen presentation. These 
Table 1. Summary of papers published so far with aim of investigating possible cross-reaction 
targets of anti-Ro/SSA and anti-La/SSB antibodies. 
- 33 - 
 
evidence prompted researchers in finding fetal susceptibility and protective genes 
that could explain the low recurrence rate of CHB (Table 2). A candidate-gene 
approach was applied by Clancy and colleagues (146) to investigate the fetal 
susceptibility to CHB of two known single-nucleotide polymorphisms (SNPs) in 
genes encoding the pro-inflammatory and pro-fibrotic cytokines TGFβ and TNFα. 
The authors revealed that the SNP in TGFβ was significantly more frequent in the 
40 children with CHB than in their 31 unaffected siblings, whereas the TNFα SNP 
was found at an increased frequency in both affected and non-affected children in 
comparison with healthy controls. However, these findings have not been 
replicated yet in a larger cohort of CHB patients.  
Several studies with different approaches found that the HLA region is a dominant 
genetic contributor to CHB development. In particular, a Genome-Wide 
Association Study (GWAS) of 116 Caucasian children with cardiac manifestations 
of NLS and of 3,351 healthy controls showed that the most significant associations 
with cardiac neonatal lupus were found in the HLA region and at location 21q22 
(147). However, comparing CHB cases with healthy controls, CHB-specific traits in 
the MHC region were not distinguished from the maternal ones, who may have 
SLE, SS and, even if asymptomatic, are genetically and immunologically different 
from the general population. Thus, the association revealed may represent the 
genetic bias present in mothers, rather than the true fetal CHB-specific 
association. Fetal HLA alleles appeared to be determinants in CHB susceptibility 
also in an in vivo study by Strandberg and colleagues (114). Using different 
congenic rat strains and a Ro52 immunization model of heart block, it was shown 
that the generation of pathogenic anti-Ro52 antibodies is restricted by maternal 
MHC, whereas susceptibility to CHB development and fetal disease outcome in 
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anti-Ro52-positive pregnancies is regulated by fetal MHC. Other evidence in favor 
to the role of HLA region in CHB were provided in a recent genetic association 
study by Meisgen and colleagues (148). In a cohort of 86 Swedish families where 
CHB pregnancies occurred, it was reported that HLA-Cw*06 and HLA-DRB1*13 
are protective alleles associated with CHB in children born to anti-Ro/SSA positive 
mothers, while HLA-DRB1*04 was found to confer susceptibility for the disease. 
Finally, a recent study reported that also non-HLA regions may confer 
susceptibility to CHB. In particular, through a GWAS of >500,000 SNPs in a 
population-based cohort of families with CHB children, it was found that Auxilin, 
the putative tyrosine-protein phosphatase encoded by DNAJC6 is a novel fetal 
susceptibility gene of CHB, with a decreased cardiac expression in presence of 
the disease risk genotype (149).  
HLA-related studies 
Associated HLA 
alleles/variants 
Method Population Reference 
B8, DR3, DQ2 associated 
to mothers with CHB 
children 
Susceptibility alleles in mothers. 
Serological typing of HLA-A, -B, -C, -
DR and -DQ  
31 mothers with CHB children, 45 
with SLE and 21 with primary SS and 
healthy children and 900 healthy 
controls 
Julkunen et 
al., 1995 
(142) 
DQB1*03/04 more 
frequent in affected 
children 
Susceptibility alleles in siblings. 
Serological typing of HLA-A, -B, -C; 
DNA-based typing of DRB1, DQA1, 
DQB1, DPB1 
6 CHB children and their 10 healthy 
siblings in 4 Finnish families 
Siren et al., 
1997 (143) 
A1, Cw7, B8 and without 
B15 associated to high 
risk of CHB 
Susceptibility alleles in  mothers. 
Serological typing of HLA-A, -B, -C; 
DNA-typing of DRB1, DQA1 and DQB1 
45 mothers with CHB children  and 32 
mothers with healthy children 
Siren et al., 
1999 (145) 
DQ1 alleles, Cw3 
associated to CHB 
Susceptibility alleles in  children. 
Serological typing of HLA-A, B and C; 
DNA-typing of DRB1, DQA1 and DQB1 
24 children with CHB and 10,000 
healthy controls (serological typing); 
91 organ donors for DNA-based 
typing 
Siren et al., 
1999 (144) 
- 35 - 
 
HLA region and 21q22 
GWAS based on genotyping of 370,000 
SNPs 
116 caucasian children with CHB and 
3351 healthy controls 
Clancy et al., 
2010 (147) 
Production of anti-Ro52 
and fetal disease 
outcome regulated by 
MHC 
Ro52-immunization in female rats with 
different MHC haplotypes 
Four MHC congenic rat strains 
Strandberg 
et al., 2010 
(114) 
Susceptibility role for   
-DRB1*04 and -Cw*05. 
Protective role for -
DRB1*13 and -Cw*06  
Low-resolution HLA-A, -Cw and –DRB1 
allele typing and family-based analysis 
86 families where CHB occured 
Meisgen et 
al., 2014 
(148) 
Non-HLA-related studies 
Associated gene/allele Method Population Reference 
None 
Susceptibility alleles in siblings. DNA-
based typing of TNF and HSP70-HOM 
6 CHB children and their 10 healthy 
siblings in 4 Finnish families 
Siren et al., 
1997 (143) 
p.Leu10Pro  in TGFβ 
more frequent in CHB 
children  
Candidate-gene approach on two 
known SNPs: c.-308G>A in TNFα and 
p.Leu10Pro in TGFβ 
88 children (40 with CHB), 74 
mothers and 102 healthy controls 
Clancy et al., 
2003 (146) 
DNAJC6  
GWAS and cardiac tissue-eQTL 
analysis on >500,000 SNPs  
Population-based cohort of families: 
92 CHB children and 256 relatives 
Meisgen et al., 
2015 (149) 
 
1.4.2 Environmental risk factors 
Several enviromental factors have been suggested to contribute to the 
development of CHB. Although neither fetal gender nor maternal disease severity 
has been associated with the disease (12, 25), it has been proposed that maternal 
age may have an influence over the outcome in anti-Ro52-positive pregnancies 
with an increased risk for CHB with increasing maternal age (150). Also in a later 
study by Ambrosi and colleagues (8), it was found that the risk for CHB outcome 
increased with maternal age in a population-based study. In the same study an 
association between the development of CHB with the season of bitrh was been 
described. Infact, there was an increased proportion of affected pregnancies in 
Table 2. Summary of papers published so far with aim of investigating genetic susceptibility of CHB 
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which the gestational susceptibility weeks 18–24 occurred during the months from 
January to March. These months are also associated to lower levels of vitamin D 
in a sample of Swedish women, suggesting a correlation between CHB and winter 
season, reduced sun exposure and vitamin D levels. However, other events linked 
to the winter season, like viral infection in the woman during pregnancy, may be 
addressed to the onset of CHB. Indeed, in a report by Tsang and colleagues 
(151), cell surface exposure of the Ro antigen in fetal cardiomyocytes following 
cytomegalovirus infection has been described. 
Another potential risk factor that has been reported in relation to CHB 
development include hypothyroidism in the mother. In particular, in a group of 87 
anti-Ro/SSA-positive women, CHB occurred in 55% of hypothyroid group and in 
13% of the normal thyroid function group. The risk for delivering a child with CHB 
in women with anti-Ro/SSA antibodies and hypothyroidism was found to be 9-fold 
higher than the risk associated to women with antibodies alone, irrespective of 
maternal condition (152). An association between hypothyroidism and CHB was 
also suggested by Askanase and colleagues (153) who found that anti-
Thyroglobulin (anti-TG) antibodies were significantly more prevalent in mothers 
with children with CHB than in women with primary SS. It may also be speculated 
that environmental and lifestyle factors such as smoking could be potential risk 
factors, but studies of such a relation to CHB are currently lacking.  
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Figure 5. Schematic representation of risk factors in congenital heart block. (Image from: Ambrosi 
and Wahren-Herlenius Arthritis Research & Therapy 2012, 14:208). 
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2. Aim of the thesis 
Part I: Identification of cross-reactive targets of anti-Ro52 
antibodies 
The aim of this study is to investigate the cross-reactivity target of anti- Ro52/p200 
antibodies in the pathogenesis of CHB, and to identify cross-reactive proteins. This 
was performed by screening a library of peptides covering the whole human 
proteome and using monoclonal antibodies specific for the Ro52/p200 region. The 
putative cross-reactive targets are studied at a peptide level, in order to 
characterize the specific epitope, and on the whole antigen level, in order to 
determine the accessibility of the epitope to the antibodies. 
 
Part II: Family-based study on HLA associations with CHB 
The aim of this multi-center study is the identification of fetal susceptibility genes 
among the Human Leucocyte Antigen (HLA) locus in anti-Ro/SSA autoantibody-
mediated CHB. DNA samples were collected from Swedish, Finnish, Norwegian 
and Italian families in which children affected from CHB were born. SNPs within 
the HLA region, the locus most significantly associated with rheumatic disorders, 
were genotyped and the transmission disequilibrium test was performed in order to 
identify unexpected parental HLA allele transmission to affected children not 
following the Mendelian rules.  
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PART I 
 
 
IDENTIFICATION OF CROSS-REACTIVE 
TARGETS OF ANTI-RO52 ANTIBODIES 
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3. Materials and methods 
3.1 Study population 
Anti-SSA/Ro and/or anti-SSB/La-positive sera from 49 mothers of fetuses with 
CHB were selected from a population-based cohort of families with at least one 
individual affected by complete third-degree CHB (90). As control population, anti-
SSA/Ro and anti-SSB/La-negative sera from 40 women without diagnosis of any 
rheumatic diseases were selected. Antibodies against Ro52, Ro60 and La were 
detected through a commercial line blot analysis (Inno-LiaTM ANA Update, 
Innogenetics, Cambereley, United Kingdom), according to the manufacturer’s 
instructions. Anti-Ro52-positive sera were later analysed for reactivity to the p200 
epitope of Ro52, using the Wieslab® SS-A p200 ELISA kit (Eurodiagnostica, 
Malmö, Sweden) according to the manufacturer’s instructions. All analyses were 
performed at the Clinical Immunology Unit, Karolinska Institutet. The sera were 
stored at -80°C. 
 
3.2 Generation of monoclonal antibodies  
In this study several monoclonal antibodies specific for different regions of the 
Ro52 protein were used. As described by Strandberg and colleagues (60), these 
antibodies have been previously produced in mouse immunized with recombinant 
human Ro52 full length protein and with the hybridoma technique. 
In particular, two antibodies specific for the p200 region, 7.2H4 (Ab11) and 
7.8C7.F10 (Ab31), and monoclonal binding Ro52 but not specific for p200, 7.2F4 
(Ab8), were used for this study (Figure 6). 
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3.3 Whole proteome microarray 
The identification of cross-reactive targets of anti-Ro52/p200 antibodies was 
performed through screening a whole proteome microarray in collaboration with 
SciLifeLab, KTH, Stockholm, Sweden (154). This technique is based on an in situ 
peptide array synthesis and subsequent antibody binding analysis (Figure 7). The 
whole human proteome array was designed based on the human Consensus CDS 
(version 37.1) protein set provided by the National Center for Biotechnology 
Information (NCBI) (155). To cover the proteome, 2.1 million 12-mer peptides 
overlapping by six amino acids were randomly distributed on the array.  
The peptide library synthesis was accomplished by means of light-directed array 
synthesis in a Roche-Nimblegen Maskless Array Synthesizer using an amino- 
Figure 6. Schematic drawing summarizing the Ro52 binding specificity of the 3 mouse monoclonal 
antibodies used in this study. 
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functionalized microscope slide as a substrate coupled with six-amino hexanoic 
acid as a spacer and amino acid derivatives carrying a photosensitive 2-(2-
nitrophenyl)propyl-oxycarbonyl group at the α-amino function. Coupling of amino 
acids to the spacer was done with pre-activation in 30 mM amino acid, 30 mM 
activator (HOBt/HBTU), and 60 mM ethyldiisopropylamine in N,N-
dimethylformamide. Washings were done with 1-methyl-2-pyrrolidinone, and site-
specific cleavage of the photosensitive protector group was accomplished by 
irradiation of an image created by a Digital Micromirror Device (Texas Instruments 
Inc., Dallas, TX), projecting light with a 365-nm wavelength. Final treatment of the 
slide with TFA/water/triisopropylsilane for 30 min cleaved off the side-chain 
protection of the amino acids. Repeated cycles of selective activation, addition of 
amino acids, and removal of excess amino acids enables parallel synthesis of 
peptides with unique sequences. 
After peptides synthesis, the slides were washed twice with TBSTT (20 mM Tris, 
0.9% NaCl, pH 7.4, 0.1% Tween 20, 0.4% Triton X-100) for 2 min, twice in TBS 
(20 mM Tris, 0.9% NaCl, pH 7.4) for 2 min, rinsed quickly three times with de-
ionized water, and dried. Primary antibody specific for p200 region of Ro52 (Ab31) 
diluted in binding buffer (10 mM Tris, 0.45% NaCl, pH 7.4, alkali soluble casein 
0.5% (Novagen, EMD Chemicals, San Diego, CA)) was injected to the array. The 
slides were incubated overnight in a NimbleGen Hybridization Station (Roche 
NimbleGen Inc.). After the primary incubation, the slide was washed twice with 
TBSTT and twice with TBS as described above. Secondary Cy3-conjugated anti-
mouse antibodies (Jackson ImmunoResearch, West Grove, PA) were diluted to 
0.15 μg/ml in binding buffer and incubated to the slide for 3 h on a shaking table. 
The slide was washed twice with TBSTT and twice with TBS as described above, 
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quickly rinsed three times in de-ionized water, and dried. The slide was 
subsequently scanned at 2-μm resolution using a NimbleGen MS200 scanner 
(Roche NimbleGen Inc.). 
The scan images were aligned and peptide feature mean fluorescence values 
were exported using the NimbleScan2 software (Roche NimbleGen Inc.). Before 
further analysis, confirmed false-positive signals caused by dirt on the arrays were 
removed. 
 
 
 
 
 
 
 
 
Figure 7. Schematic representation of the whole-proteome microarray that was performed for the 
identification of cross-reactive targets of anti-p200 antibodies. (A) Depiction of peptide library 
synthesis by means of selective activation of square features on the array through light reflected 
by digital micromirrors. (B) Schematic picture of incubation of the peptide array with the primary 
antibody and fluorophore-labeled secondary antibody. (C) A scan image of a part of the peptide 
array in which the bright spots correspond to peptide features bound by antibodies (Image from:  
Forsström B et al., Mol Cell Proteomics. 2014;13:1585-97) 
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3.4 Synthetic peptides and proteins 
Five different synthetic peptides were used in this study and their sequences are 
illustrated below: 
 p200:  LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSS 
 pGAK: PEIIDLYSNFPI 
 pTG:  SQYPGSYSDFST 
 biotinylated pGAK biotin-aminohexanoic acid-YRTPEIIDLYSNFPI 
 biotinylated pTG biotin-aminohexanoic acid-GQLSQYPGSYSDFST 
Briefly, human p200 peptide corresponding to amino acid 200-239 of the human 
Ro52 protein and containing the main CHB related epitope was included and was 
purchased from Thermo BioSciences, Ulm, Germany. PGAK and pTG have the 
same protein sequence of the peptides used in the whole proteome microarray. 
Biotinylated pGAK and biotinylated pTG contain the same protein sequence of 
pGAK and pTG, respectively, and are conjugated to a biotin molecule through a 
linker aminohexanoic acid at the N-terminal molecule. These peptides were 
purchased from TAG Copenhagen A/S (Frederiksberg, Denmark). Purity was 
confirmed to be >90% by high-performance liquid chromatography and mass 
spectrometry. 
 
3.5 Confirmation of cross-reactivity to peptides 
3.5.1 Competitive ELISA 
Competitive ELISA with a pre-incubation step was performed to investigate the 
cross-reactivity of anti-Ro52 monoclonal antibodies to the selected peptides. High-
binding 96-well plates (Nunc, Odense, Denmark) were coated with 1 μg per well of 
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recombinant full-length Ro52, p200 or maltose binding protein (MaBP) and diluted 
in carbonate buffer, pH 9.6. When Ro52 or MaBP were the antigens, plates were 
coated overnight at +4°C; when p200, coating was performed overnight at room 
temperature and for at least 24 hours at 4°C before use. Plates were blocked with 
phosphate buffered saline (PBS)/0.05% Tween/5% milk powder for 1 hour. 
Monoclonal antibodies (mAbs) and sera were tested at a dilution of 0.1µg/ml and 
1:1,000, respectively, in PBS/0.05% Tween/1% milk powder. Bound antibodies 
were detected by affinity-purified, alkaline phosphatase (AP)-conjugated anti-
mouse or anti-human IgG antibodies (Dakopatts, Glostrup, Denmark). 
Phosphatase substrate tablets (Sigma) dissolved in diethanolamine buffer, pH 9.8, 
were used as substrate and incubated for 30 minutes for detection of IgG. The 
absorbance was measured at 405 nm. Between each step, plates were washed 
four times with wash buffer (0.25M NaCl, 0.05% Tween/1 liter of de-ionized water). 
All steps were performed at room temperature except coating, which was 
performed at 4°C. Sera from healthy subjects lacking anti-Ro52 antibodies and 
mAb8, not specific for p200 region, were used as controls, and showed an optical 
density (OD) of <0.1 in all readouts. All mAbs and sera were tested for antibodies 
to the MaBP fusion partner of the recombinant Ro52, showing OD values <0.1 in 
all cases. All mAbs and sera were run in duplicate. 
Cross-reactivity of mAbs and sera to the peptides was analysed in anti-p200 and 
anti-Ro52 competitive ELISA with a pre-incubation step. In this phase diluted 
mAbs or sera were incubated with serial dilution of p200, pGAK, pTG, and MaBP 
in concentrations ranging from 0.025-0.1 mg/ml for 1h at room temperature prior to 
analysis in ELISA as described above. Incubation with only PBS/0.05% Tween/1% 
milk powder was also performed.  
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3.5.2 Biotinylated-peptides ELISA 
Pierce™ Streptavidin Coated High Capacity 96-wells plates (Thermo Fisher 
Scientific, Waltham, Massachusetts, United States) were coated overnight at room 
temperature with 1µg per well of biotinylated peptides diluted in Tris-buffered 
saline (25mM Tris, 150mM NaCl; pH 7.2)/0.05% Tween/0.1% BSA. Monoclonal 
antibodies (mAbs) and sera were tested at a dilution of 5µg/ml and 1:300, 
respectively, in Tris-buffered saline/0.05% Tween/0.1% BSA and plates were 
incubated at room temperature for 2h. The experiment, then, proceeded as 
described above for anti-p200 and anti-Ro52 ELISA. 
3.5.3 Anti-Thyroglobulin ELISA 
The DIASTAT anti-Thyroglobulin (Tg) ELISA kit (Eurodiagnostica, Malmö, 
Sweden) was used to analyse the cross-reactivity to Tg of mAbs and sera 
according to the manufacturer’s instructions with slight modifications. Monoclonal 
antibodies (mAbs) and sera were tested at a dilution of 5µg/ml and 1:100, 
respectively, in diluent buffer and plates were incubated for 1h at room 
temperature. Unbound antibodies were washed away with wash buffer (5 times). 
The experiment was then performed as described above for anti-p200 and anti-
Ro52 ELISA  
Cross-reactivity of mAbs and sera to the peptides were analysed in anti-Tg 
competitive ELISA with a pre-incubation step. In this step diluted mAbs or sera 
were incubated with serial dilution of p200, pTG, Tg and MaBP in concentrations 
ranging from 0.1-0.2 mg/ml for 1h at room temperature prior to analysis in ELISA 
as described above. Incubation with only diluent buffer was also performed. 
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3.6 Study of cross-reactivity to Cyclin G-associated 
kinase (GAK)  
3.6.1 Transfection 
HEK293T cells were cultured in 75cm2 flask (Sarstedt AG & Co, Nümbrecht, 
Germany) with Dulbecco’s Modified Eagle Medium (DMEM, Sigma), 
supplemented with 5% Fetal calf serum (FCS), 2mM L-glutamine, 500U/ml 
penicillin, 0.01mg/ml streptomycin, 1mM Hepes (Sigma) and 10mM Sodium 
Pyruvate (Sigma). Sixteen hours before transfection, 4 x 106 cells were seeded per 
well in 6-wells plates (Sarstedt). Transfection was performed in duplicates with the 
following plasmids: pGAK-tGFP containing human GAK (Origene Technologies©, 
Rockville, Maryland, United States), pGFP-Ro52 with Ro52, pGFP-DNAJC6 
containing DNAJC6 (NM_001256864). All the genes represented human isoforms 
with full-length, recombinant sequence tagged with GFP at the N-terminal, except 
GAK, which was fused with the isoform turboGFP (tGFP) at the C-terminal. Cells 
were transfected with also plasmid containing only GFP (pGFP). One µg of 
plasmids was transfected 100µl of pure DMEM and 3µl X-tremeGENE™ 9 DNA 
transfection reagent per each well. Negative control transfection was also 
performed by adding the transfection mix without DNA. Twenty-four hours after 
transfection, fluorescence emission was checked with a fluorescence microscope 
to check the efficacy of transfection. Cells were, then, washed with PBS and 
brought in suspension, centrifuged for 5’ at 500 x g at room temperature to pellet 
them.  
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3.6.2 Protein sample preparation 
After centrifugation, pellets containing cells were lysed with 100µl of lysis buffer 
constituted by Cell lytic M cell Lysis reagent (Sigma) and 1% of Halt Protease and 
Phosphatase inhibitor cocktail 100x (Thermo Fisher). The mixture was kept for 15’ 
in agitation and then centrifuged for 15’ at 15 x 103 rpm to pellet cellular debris. All 
these steps were performed at +4°C. Supernatant containing protein was saved 
and protein concentration was measured using DC protein Assay (Bio-Rad 
Laboratories AB, Hercules, California, U.S.A.) following the manufacture’s 
recommendations and using a standard curve composed of 6 serial dilutions in 
PBS of BSA in known concentration ranging from 2mg/ml to 0.125mg/ml. Briefly, 
25µl of activated reagent A and 200µl of reagent B were added to 5µl of 1:10 pre-
diluted samples or standards or PBS only in duplicate to 96-well plates. 
Absorbance was read at 650nm after 15’ of incubation. Proteins were, then, 
denaturated by boiling for 5’ in 5% sodium dodecyl sulfate (SDS) sample buffer. 
3.6.3 SDS-page and Western-blot 
Twenty µg of proteins from each transfection experiment lysate were loaded on 
4%-12% SDS-polyacrylamide gel electrophoresis (PAGE) gels. Proteins were 
transferred by electrophoresis onto nitrocellulose membranes and blocked for 1 
hour with PBS/0.05% Tween/5% milk powder at room temperature and in 
agitation. Thereafter, filters were incubated overnight at +4°C with Ab31, patient 
sera, diluted to 1µg/ml or 1:500, respectively, in PBS/0.05% Tween/1% milk 
powder. Mouse monoclonal anti-tGFP (Origene) and rabbit anti-GFP (Life 
Technologies) diluted to 1µg/ml and to 2µg/ml respectively, were used to detected 
the fusion protein GFP. To detect bound antibodies, membranes were incubated 
for 1 hour at room temperature with anti-human, anti-mouse or anti-rabbit IgG 
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antibodies HRP-conjuated (Dakopatts), diluted 1:2,000 in PBS/Tween/1% milk 
powder. As loading control detection of the housekeeping protein β-actin was 
revealed with a mouse anti-β-actin HRP-conjugated antibody diluted 1:20,000 in 
PBS/Tween/1% milk powder. Amersham ECL Western Blotting Detection Reagent 
(GE Healthcare, Little Chalfont, United Kingdom) was used as substrate to reveal 
bands in correspondence of bound antibodies. Membranes were washed in 
PBS/0.05% Tween between each step and all incubations were done in agitation. 
3.7 Statistical analysis 
Comparison of antibodies values between anti-Ro52-positive and anti-Ro52-
negative population was performed with the non-parametric Mann-Whitney U-test. 
Fisher’s exact test was used to compare the frequency of antibody positivities 
between the two groups. All the analysis were done using GraphPad Prism V.5.01 
(GraphPad Software, San Diego California, USA). A p-value <0.05 was considered 
significant. 
3.8 Bioinformatic tools 
Clustal Omega (University College of Dublin, Dublin, Ireland, 
http://www.ebi.ac.uk/Tools/msa/clustalo/,) is a multiple sequence alignment 
program that uses seeded guide trees and HMM profile-profile techniques to 
generate alignments between three or more sequences. This tool was used to 
align the sequence of the cross-reactive peptides. 
The Basic Local Alignment Search Tool (BLAST), (National Center for 
Biotechnology Information, U.S. National Library of Medicine, Bethesda MD, USA, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi) is an algorithm that finds regions of local 
similarity between sequences. The program compares nucleotide or protein 
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sequences to sequence databases and calculates the statistical significance of 
matches. BLAST can be used to infer functional and evolutionary relationships 
between sequences as well as help identify members of gene families. 
Specifically, BLASTp, was used in this study to analyze the sequence similarity 
between two proteins. 
The Protein Data Bank (PDB; http://www.rcsb.org/pdb/home/home.do) is a 
crystallographic database for the three-dimensional structural data of large 
biological molecules, such as proteins and nucleic acids. The data, typically 
obtained by X-ray crystallography, NMR spectroscopy, are freely accessible on the 
Internet (156). This tool was used to get the protein structure of GAK (PDB ID: 
4C57) and to check where the epitope sequence is localized. 
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4. Results 
4.1 Cross-reactive peptides revealed by the whole 
proteome microarray 
To identify cross-reactive targets of anti-Ro52/p200 antibodies a screening on 2.1 
million 12-mer peptides covering the human proteome using the monoclonal 
antibody Ab31 was undertaken. In the whole proteome microarray, anti-p200 
monoclonal antibodies bound significantly to 17 peptides. The sequence of each 
peptide with the corresponding bar of intensity of cross-reactivity of Ab31 is 
depicted in Figure 8.  
Figure 8. Graph representing the intensity of binding of monoclonal Ab31 to the 12-mer peptides. 
Purple bars correspond to pairs of six amino acid-overlapped peptides. Green bars correspond to 
sequences that are solely bound. 
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Aligning the amino acid sequence of the cross-reactive peptides to the human 
protein databases with blastp it emerged that they were contained in 12 different 
proteins. In particular, 7 peptide sequences were found uniquely in 7 proteins, 
while the remaining 10 ones were mapped in 5 proteins, as the monoclonal Ab31 
bound pairs of adjacent and overlapped by 6 amino acids peptides (Table 3). Each 
pair of overlapped cross-reactive peptides allowed identification of a cluster of 
minimal epitopes of cross-reactivity shown by Ab31 binding these amino acid 
sequences:  
  “SCYSDF”: “Ser-Cys-Tyr-Ser-Asp-Phe” 
 “DSYSNF”: “Asp-Ser-Tyr-Ser-Asn-Phe” 
 “ENYSNF”: “Glu-Asn-Tyr-Ser-Asn-Phe” 
 “YSDFST”: “Tyr-Ser-Asp-Phe-Ser-Thr” 
Table 3. Table showing the protein sequence of the cross-reactive peptides and in which protein 
they are included. The first 10 sequences correspond to paired overlapped peptides that share a 
minimal epitope.   
PROBE_SEQUENCE Minimal epitope Gene
NSCKEMSCYSDF SCYSDF FMO1
SCYSDFPFPEDY SCYSDF FMO1
NVCKEMSCYSDF SCYSDF FMO4
SCYSDFPFHEDY SCYSDF FMO4
SNSTEQDSYSNF DSYSNF C3orf63
DSYSNFQVYHSQ DSYSNF C3orf63
YRDVMWENYSNF ENYSNF ZFP14
ENYSNFISLGPS ENYSNF ZFP14
SQYPGSYSDFST YSDFST TG
YSDFSTPLAHFD YSDFST TG
ITPVFSDFPVHG NPC1
LYPFSLPYSDFP MRPL4
MMEVESSYSDFI PKIG
SDFPCSDTFSNF LPIN1
PEIIDLYSNFPI GAK
VLDSVNATYSDF CDC20B
THDQDYSNFSSS SLC39A12
Protein  
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In an attempt to investigate if the cross-reactive sequences had a conserved motif 
and to refine the cross-reactive epitope, multiple alignment of the 17 sequences 
was performed with Clustal Omega. The alignment revealed that all these peptides 
shared the “YSDF” (Tyr-Ser-Asp-Phe) or “YSNF” (Tyr-Ser-Asn-Phe) amino acidic 
sequences (Figure 9).  
 
4.2 Cross-reactivity to Thyroglobulin 
Among the cross-reactive peptides, the one generating the strongest positive 
signal of binding by Ab31 was contained within Thyroglobulin (Tg). Notably, 
hypothyroidism has been associated with CHB (152). In order to investigate and 
confirm cross-reactivity to this target, ELISA coated with a biotinylated Tg peptide 
(pTG) was performed. When running monoclonal antibodies towards different 
regions of Ro52, it was found that Ab11 and Ab31, specific for the p200 region, 
Figure 9. Representation of the multiple alignment of the cross-reactive peptides. Encircled in red 
are the two epitope sequences “YSNF” and “YSDF” shared by all the peptides. 
- 58 - 
 
bound biotinylated pTG 3.1 - 2.7-fold stronger than Ab8, not p200 specific (Figure 
10).  
After monoclonal antibodies, cross-reactivity to pTG was investigated also in sera 
from mothers who gave birth to babies with CHB. A cut-off value for a positive 
signal in the assay for binding to biotinylated pTG was established as the 95° 
percentile in sera from 40 anti-SSA/Ro and anti-SSB/La-negative women without 
any diagnosis of rheumatic disease. According to this, 24.4% of sera of mothers 
with CHB children were positive for binding to pTG, while only 5% of controls 
were, revealing a significant difference of frequency of positivities (p=0.017) and 
median (0.064 vs 0.023, p<0.0001) between the two populations (Figure 11 A and 
B).  
  
 
 
Figure 10. Graph illustrating the binding of monoclonal antibodies anti-Ro52 Ab8, Ab31 and Ab11 
to biotinylated pTG. 
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After confirming the binding to pTG at a peptide level, we wanted to investigate if 
anti-p200 can bind also to the whole TG antigen. In order to do this, monoclonal 
anti-Ro52 antibodies and anti-p200-positive sera were analysed in anti-TG ELISA. 
The monoclonals Ab31 and Ab11, specific for the p200 region, bound TG and did 
so a 3.7 and 10-fold stronger than Ab8, which is not p200 specific. In contrast, 
monoclonal antibodies towards the intracellular antigens IRF-1 and IRF-5 were 
used as controls and did not bind TG (Figure 12 A). Five anti-p200 positive sera 
from mothers with CHB children which exhibited the highest cross-reactivity to 
biotinylated pTG, showed different reactivity to TG: from low (sera number 1, 3, 4), 
to high binding to TG (sera 2, 5) (Figure 12 B), indicating that the binding to the 
pTG epitope is not merely a reflection of TG autoantibodies. 
 
Figure 11. A: graph illustrating the distribution of value of cross-reactivity to pTG of the two 
population. B: representation of distribution of value of cross-reactivity to pTG with division of 
patients positive and negative for cross-reactivity to pTG. 
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To further investigate the specificity of cross-reactivity of anti-p200 antibodies to 
pTG, we performed competition experiments based on pre-incubation of 
monoclonal antibodies with pTG followed by testing their binding to TG and p200 
in ELISA. For this experiment, Ab11 was chosen as it was the one showing 
highest reactivity to biotinylated pTG (Figure 10). Incubation of Ab11 with pTG 
decreased the binding to TG by up to 53.5% in a concentration-dependent 
manner, compared with the pre-incubation with buffer only. Incubating Ab11 with 
the specific 0.1mg/ml and 0.2mg/ml of p200 instead reduced the binding to 10% 
and 0.5%, respectively (Figure 13). Incubation of Ab11 with pTG also decreased 
the binding to p200 with up to 14% in a concentration-dependent manner, 
compared to the pre-incubation with only buffer (Figure 13). In all the experiments, 
incubation with MaBP, used as a negative control, did not inhibit the binding of 
antibodies to the target in ELISA. 
 
 
 
Figure 12. Graphs illustrating the binding of monoclonal antibodies (A) and sera (B) to TG. 
A B 
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In order to assess if reactivity to TG shown by anti-p200-positive sera (Figure 12B) 
was due to presence of anti-TG antibodies and to investigate the specificity of 
cross-reactivity to TG, competition experiments with a pre-incubation step, as for 
monoclonal antibodies, were performed. Pre-incubation of sera with pTG reduced 
the binding to TG up to 30% in a concentration-dependent manner (Figure 15 A). 
Specificity of cross-reactivity to TG by anti-p200 antibodies was revealed when 
sera, incubated with p200, showed a decreased binding to TG up to 47% in a 
Figure 14. Graphs illustrating the binding of Ab11 to p200 after incubation with different 
concentration of p200, pTG and MaBP. 
Figure 13. Graphs illustrating the binding of Ab11 to TG after incubation with different concentration 
of p200, pTG and MaBP. 
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concentration-dependent manner (Figure 15 B). These data, together, indicate that 
reactivity to TG was due partly to the presence of anti-TG antibodies, but also to 
cross-reactivity of anti-p200 antibodies. 
 
 
 
 
4.2.1 Reactivity to Thyroglobulin at peptide level 
The cross-reactivity of anti-Ro52 monoclonal antibodies and sera from mothers of  
 
 
4.3 Cross-reactivity to GAK 
4.3.1 Analysis at peptide level 
Among the peptides bound by the monoclonal Ab31 in the whole proteome 
microarray, we wanted to investigate the cross-reactivity to the peptide included in 
GAK/Auxilin2 (Cyclin G Associated Kinase). In fact, this gene shares highly 
similarity to DNAJC6/Auxilin (DnaJ heat shock protein family (Hsp40) member 
C6), which has been recently indicated as a novel fetal susceptibility gene for CHB 
as well as functionally associated to CHB (149). In an attempt to confirm cross-
reactivity to the peptide GAK (pGAK), ELISA coated with biotinylated pGAK was 
performed. When running monoclonal antibodies towards different regions of 
Ro52, it was found that Ab31 and Ab11, specific for p200 region, bound 
Figure 15. Graphs illustrating the binding of sera to TG after incubation with different concentration 
of, pTG (A) and p200 (B). 
A B 
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biotinylated pGAK 7.3 – 7 fold stronger than Ab8, which is not p200 specific 
(Figure 16). 
 
As for pTG, cross-reactivity to pGAK was investigated also in sera. The cut-off of 
reactivity to pGAK was found to be 0.132 O.D. According to this, 22.4% of sera of 
mothers with CHB children were positive for cross-reactivity to pGAK, while only 
5% of controls were, revealing a significant difference of frequency of positivities 
(p=0.032) and median (0.081 vs 0.038, p=0.0014) between the two populations 
(Figure 17 A and B). 
 
 
 
 
 
Figure 16. Graph illustrating the binding of monoclonal antibodies anti-Ro52 Ab8, Ab31 and Ab11 
to biotinylated pGAK. 
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To further investigate the specificity of cross-reactivity of anti-p200 antibodies to 
pGAK, competition experiments based on pre-incubation of monoclonal antibodies 
with pGAK followed by testing their binding to p200 and to Ro52 in ELISA were 
performed. For this experiment, Ab31 was chosen as it was the one showing the 
highest reactivity to biotinylated pGAK (Figure 16). Incubation of Ab31 with pGAK 
decreased the binding to p200 up to 21% in a concentration-dependent manner, 
compared to the pre-incubation with only buffer (Figure 18). Incubating Ab31 with 
pGAK reduced the binding to Ro52 up to 43%, compared to the pre-incubation 
with only buffer (Figure 19). In all the experiments, incubation with MaBP, 
considered as negative control, did not inhibit the binding of antibodies to the 
target in ELISA. 
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Figure 17. A: graph illustrating the distribution of value of cross-reactivity to pGAK of the two 
population. B: representation of distribution of value of cross-reactivity to pGAK with division of CHB 
mothers into two sub-population, according to positive and negative reactivity to pGAK. 
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Incubation of anti-p200-positive sera from mothers with CHB children with pGAK, 
instead, did not affect the binding to p200 in ELISA. However, incubation of the 
same sera with p200 as positive control, reduced the reactivity to p200 in ELISA 
only to 30% - 50%, indicating that the amount of antibodies present in the sera 
was still too high to be inhibited by pGAK. 
 
Figure 18. Graphs illustrating the binding of Ab31 to p200 after incubation with different 
concentration of p200, pGAK and MaBP. 
Figure 19. Graphs illustrating the binding of Ab31 to p200 after incubation with different 
concentration of p200, pGAK and MaBP. 
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4.3.2 Cross-reactivity at whole antigen level 
After confirming the cross-reactivity to GAK at the peptide level, we wanted to 
examine if anti-p200 antibodies can also bind detectably to the whole GAK 
antigen, or rather if the specific epitope of cross-reactivity is exposed for binding of 
antibodies. First, analysis of the cross-reactive “YSNF” epitope was performed on 
the published 3D structure of the GAK protein based on the X-ray cristallography 
structure (157). This analysis revealed that the cross-reactive epitope is located in 
a flexible activation segment in the external side of the protein (Figure 20). 
 In order to study if anti-p200 antibodies can cross-react to the whole GAK protein, 
overexpression of a cloned plasmid encoding recombinant tGFP-tagged GAK  in 
HEK293T cells with following  Western blot of protein lysates was performed. On 
blotted membranes, Ab31 bound to recombinant GAK, revealing a band at 
169KDa, at the same level of the band recognized by anti-tGFP antibodies, 
directed to the fusion protein tGFP. This band appeared only in cells transfected 
with GAK, and not in non-transfected cells or control vector tranfected cells. Ab11, 
on the other hand, did not bind GAK in GAK-transfected cells, but rather revealed 
Figure 20. Three-dimensional structure of GAK, with representation of the cross-reactive epitope 
“YSNF” in circles. 
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unspecific bands at 150-160KDa in transfected and untransfected cells. As 
positive controls, Ab11 and Ab31 bound to the recombinant eGFP-Ro52 (81KDa) 
(Figure 21).  
 In order to study the specificity of cross-reactivity of Ab31 to GAK, two Western 
blot membranes with GAK overexpressed lysates, previously incubated with Ab31 
and anti-tGFP (Figure 22 A), were stripped of bound antibodies (Figure 22 B), and 
then incubated with the reciprocal antibodies (Figure 22 C). In this way it was seen 
that Ab31 and tGFP bound to recombinant GAK-GFP at the same molecular 
weight (169kDa). 
 
 
Figure 21. Western Blots to study cross-reactivity of Ab11 and Ab31 to recombinant GAK. On the 
left ladder with correspondent molecular weight; Braces indicates with which antibody and relative 
concentration the membranes were incubated. On the top of membranes loading order of cell 
lysates, with the correspondent overexpressed gene is reported.  
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Other than monoclonal antibodies p200-specific, binding to the whole GAK protein 
was also analyzed in 5 sera that showed the highest reactivity to pGAK in ELISA. 
After exposure three out of five sera bound to GAK with different strenght, 
revealing a band at the same level as the one revealed by the anti-tGFP antibody 
(Figure 23). 
 
Figure 22. Western Blots to study specificity of cross-reactivity of Ab31 to recombinant GAK. On 
the left ladder with correspondent molecular weight of the bands. A: membrane 1 was incubated 
with anti-tGFP and membrane 2 with Ab31. B: bound antibodies were removed from membranes. 
C: Membrane 1 was incubated with Ab31 and membrane 2 with anti-tGFP. 
Figure 23. Western Blots to study specificity of cross-reactivity of sera to recombinant GAK.  
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4.3.3 Differential cross-reactivity to GAK and Auxilin 
 After confirming that the whole GAK antigen can be bound both by p200-specific 
monoclonal antibodies and by anti-p200-positive sera, we focused on the similarity 
of GAK with Auxilin. In particular we wanted to investigate if the cross-reactive 
epitope is present also in Auxilin and if the protein can be bound by anti-p200 
antibodies. Aligning the two protein sequences it was observed that the two 
proteins have 58% of sequence homology but that the “YSNF” epitope is present 
only in GAK, in a protein kinase domain that is missing in Auxilin (Figure 24). 
According to the result of the protein alignment, the monoclonal antibody Ab31 did 
only bind to GAK in Western blot and not to Auxilin, indicating a specific cross-
reactivity towards this protein (Figure 25). 
Figure 24. Representation of domain structure of GAK and Auxilin with focus on position of the 
cross reactive epitope, underlined in yellow. 
Figure 25. Western Blots to study the possible cross-reactivity to Auxilin.  
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5. Discussion 
Association of anti-Ro/SSA and anti-La/SSB antibodies with CHB is well 
established (19-21), but the pathogenic mechanism of this disease is far from 
being completely elucidated (139). The intracellular localization of Ro52, Ro60 and 
La proteins and the lack of evidence that maternal antibodies can cross the 
sarcolemma of a normal cardiomyocyte and bind to the specific antigens are the 
biggest obstacle in understanding the molecular mechanism leading to CHB. 
Based on these fact, it has been proposed that anti-Ro52 antibodies may mediate 
their pathogenic effect on fetal hearts by cross-reacting with other target/targets 
available in the extracellular space. So far, several cross-reactive targets have 
been proposed, from the cardiac 5-HT4 serotoninergic receptor to L-Type and T-
Type calcium channels and α-Enolase (123, 124, 130-133, 136). Even though 
each of the suggested cross-reactive target is supported by experimental findings, 
contradictory data from other studies have also emerged with regard to the same 
proteins (125, 126, 135, 138). Notably, none of them was confirmed to be a main 
cross-reactive target recognized by most of the sera analyzed from mothers with 
CHB-children. Furthermore, cross-reactivity of the subset of anti-Ro52 antibodies 
specific for p200 region, the major antigenic part of Ro52 molecule, has not been 
deeply investigated yet. 
In this context a screening based on 12-mer peptides covering the whole 
proteome was undertaken using a monoclonal antibody specific for p200 (Ab31). 
Basing the screening on 12-mer peptides enabled antibodies to recognize only 
linear epitopes, that depend only on the primary sequence and are not based on 
the tertiary structure of the proteins. Including an overlap in the peptides by 6 
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amino acids also increased the chance for the antibodies to bind the targets and 
reduced the risk of the loss of epitopes at the extremities of one sequence. With 
this array, 17 peptides were found to be cross-reactive with Ab31. Interestingly, 2 
repeated linear motifs were shared among these peptides, suggestive of 
consituting the epitope of cross-reactivity recognized by anti-p200 antibodies. The 
amino acid sequence of the two epitopes is similar between each other, “YSDF” (N 
term-Tyr-Ser-Asp-Phe-C term) and “YSNF” (N term-Tyr-Ser-Asn-Phe-C term). The 
only difference in the motif is the presence in the third position of an acid aspartic 
(Asp, D) or an asparagine (Asn, N), which diverge only by the presence of an 
amine group in the latter amino acid (Figure 26). 
Among the cross-reactive targets, thyroglobulin was thought to be interesting from 
the pathogenic point of view, considering that hypothyroidism was previously 
revealed to be a risk factor for CHB development in anti-Ro/SSA-positive 
pregnancies (152) and anti-TG antibodies were found in 33% of mothers with CHB 
children (153). In the current study, reactivity to pTG was confirmed for the 
monoclonal antibodies to p200 (Ab11 and Ab31), and found to be positive in 
24.4% of anti-p200-positive sera from mothers having children with CHB. In 
addition to reactivity at the peptide level, reactivity was also seen to the whole TG 
protein with Ab11 and in sera. Finally, competition experiments based on pre-
YSDF sequence YSNF sequence 
Figure 26. Primary protein structure of the two cross-reactive epitopes. 
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incubation of sera with pTG or p200 followed by testing their binding to TG in 
ELISA showed that reactivity to TG was due to both presence of anti-TG 
antibodies and specific cross-reactivity of anti-p200 to pTG. According to the 
previous findings where anti-TG antibodies were significantly more prevalent in 
CHB mothers than in women with primary SS (152), we here found significantly 
higher prevalence of reactivity to pTG in CHB mothers compared to the control 
group. As the p200 antibodies were able to bind the whole TG protein, it is likely 
that the cross-reactive epitope is located on the exterior of the molecule. 
Unfortunately, the three-dimensional structure of this protein is not known and we 
cannot confirm the exact spatial location of the epitope.  
TG is a glycoprotein synthesized in thyrocytes (158) and plays an important role in 
the synthesis of thyroid hormones T3 and T4 (159). After synthesis, TG is 
transported and stored in the follicular lumen of the thyrocyte (160), where the 
tyrosine residues of TG undergo iodination to produce mono- (MIT) and di-
iodotyrosines (DIT) catalyzed by thyroid peroxidase (161) and hydrogen peroxide 
(162). Subsequent coupling of these iodotyrosines produces T3 and T4 (163, 164). 
TG is pinocytosed into the thyroid cell (165) and undergoes proteolysis by 
lysosomes to release T3 and T4 (166), which are then secreted into the 
bloodstream (167). TG was also reported to be expressed in Follicular Dendritic 
Cells in the context of Thyroid Mucosa-Associated Lymphoid Tissue (MALT) 
lymphoma (168). Immunogenicity of TG is long known (169-171), and indeed it is 
the major autoantigen in both Hashimoto’s and Grave’s diseases (172). In this 
context, it would be interesting to find the connection between the higher 
prevalence of anti-TG antibodies in women with CHB pregnancy and cross-
reactivity to TG of anti-p200 antibodies. Considering the limited expression of TG 
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to thyroid gland and to MALT lymphoma and that the etiology of anti-TG antibodies 
is not known, more studies are needed to unravel their biological involvement in 
the pathogenesis of CHB. 
Other than TG, among the cross-reactive targets of the whole proteome 
microarray, cross-reactivity of anti-p200 antibodies was further investigated for the 
peptide included in GAK. The interest for this target arose because GAK shares 
58% of sequence homology with Auxilin, recently reported as a novel fetal 
susceptibility gene genetically and functionally associated to CHB (149). In this 
study, binding to pGAK was confirmed with monoclonal antibodies binding p200 
(Ab11 and Ab31) and found to be positive in 22.4% of anti-p200-positive sera from 
mothers having children with CHB. Analysis of the three-dimensional protein 
structure revealed that the cross-reactive epitope was located on the external side 
of the molecule and, hence, most likely accessible to be bound by antibodies. This 
was confirmed with western blot demonstrating that the monoclonal antibody Ab31 
and sera from mothers with children affected from CHB bound to the whole GAK 
protein, but not Ab11. Further experiments would be needed to test if the reactivity 
to GAK seen in sera is generated by anti-p200 antibodies or by the presence of 
antibodies primarily specific for GAK. A possible approach would be the 
purification of anti-p200 antibodies from sera and analysis of their binding to GAK 
and/or the binding to p200 of the purified immunoglobulins after incubation with 
pGAK. Despite the high similarity between GAK and Auxilin, binding of anti-p200 
antibodies was specific for GAK. This is not surprising as the cross-reactive 
epitope is not present in the latter. Cyclin G associated kinase (GAK) was first 
identified in experiments investigating proteins associated with cyclin G, a protein 
involved in cell cycle regulation (173). GAK (also known as Auxillin 2) is a 169 kDa 
- 75 - 
 
serine/threonine protein kinase that belongs to the numb-associated kinase (NAK) 
family. GAK is a key regulator of clathrin-mediated trafficking in both the endocytic 
and secretory pathways. It recruits clathrin and clathrin adaptor protein complex 2 
(AP-2) to the plasma membrane (174) and stimulates its binding to cargo proteins 
and enhances cargo recruitment, vesicle assembly, and efficient internalization 
(174-177). Moreover, GAK regulates endocytosis of receptors mediated by 
alternate clathrin adaptors (174) and is implicated in later steps of endocytosis, 
including regulation of clathrin-coated vesicles uncoating, which enables recycling 
of clathrin back to the cell surface (174, 176). GAK also plays an important role in 
regulating clathrin-mediated sorting events in the trans-Golgi network (174, 176). 
GAK is an important regulator of epidermal growth factor receptor (EGFR); it is 
known to promote EGF uptake (174) and may also function in receptor signaling 
(178). GAK has a central role in development, as GAK-/- mice died early in 
gestation, and also in adult viability, as conditional knock out of the gene in adult 
mice caused death of these animals (179). GAK is expressed ubiquitously with 
peaks of expression in testis, heart and skeletal muscle (180) and bears a strong 
homology (58%) to the protein Auxilin, but it has an additional serine/threonine 
kinase domain at the N-terminal, where the cross-reactive epitope is located. 
Auxilin is a brain- and heart-specific cofactor of heat shock cognate 70 (Hsc70) 
and plays a role in uncoating clathrin-coated vesicles by Hsc70 (181-183). 
Meisgen and colleagues have recently found that Auxilin is a novel fetal 
susceptibility gene for CHB (149). In particular, the risk genotype is associated to a 
lowered expression of Auxilin in the fetal heart and deletion of the gene in mice 
caused calcium disturbance in cardiomyocytes and disregulation of calcium 
channel expression on the surface of the cells. 
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It is to note, though, that GAK is an intracellular protein, with localization to the 
nuclear membrane, to the filamentous network of the endoplasmic reticulum and 
associated to focal adhesion, (180, 184). The relevance of reactivity to GAK would 
need to be further investigated. It might be speculated that, in fetuses with the risk 
genotype for Auxilin, a prolonged calcium disturbance and an impaired clathrin-
dependent traffic of vesicles might lead to exposure of GAK to the surface, where 
it would be available for binding by the maternal anti-Ro52 antibodies. 
Since GAK and Auxilin are involved in the same cellular pathway of clathrin-
mediated trafficking and Auxilin has already been functionally associated to CHB, 
it would be interesting to further investigate their simultaneous effect in the 
development of CHB. Correlation of the profile of reactivity to GAK in sera with the 
corresponding genotype of Auxilin could be done in anti-p200-positive women with 
CHB children. If a positive binding to GAK corresponds to the presence of the risk 
genotype for Auxilin in the same patients, this would support the association of an 
impaired clathrin-dependent traffic of vesicles with the development of the disease. 
It is worth to note that the two targets analysed in this study, TG and GAK, were 
recognized differently by the two monoclonal anti p200 antibodies used. At peptide 
level, both antibodies Ab11 and Ab31 cross-reacted similarly. At the whole antigen 
level however, Ab11 bound TG more than 2-fold stronger than Ab31 did (Figure 
12A), while only Ab31 was able to bind GAK. This difference can be due to the 
different techniques used to determine the binding to the two proteins, ELISA for 
TG and Western blot for GAK. However, it might be that the differential behaviour 
of the two monoclonal antibodies is target-specific. If this is confirmed, we can 
suggest that anti-p200 antibodies might have different targets of cross-reactivity, 
depending on which part of the p200 region they are specific for. If this concept is 
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extended to the whole specificities of anti-Ro52, anti-Ro60 and anti-La antibodies, 
we can speculate that several cross-reactive targets could exist and vary among 
each patients sera. According to this hypothesis, each cross-reactive target could 
account for a subset of patients. Consistently, in our study, positive reactivity to 
pTG and to pGAK was seen, respectively, for 24.4 and 22.4% of sera and also in 
the previous studies the putative cross-reactive targets haven’t been recognized 
by 100% of sera analysed, leading to an intriguing scenario of several cross-
reactive targets involved in the pathogenesis of the CHB. The recently developed 
platforms for profiling of autoantibody repertoires based on high-density protein 
microarray of recombinant proteins fragments (185, 186) could be an useful tool 
for determination of cross-reactivity profiles of different sera in order to identify 
common cross-reactivity targets or pathways involved in the pathogenesis of CHB. 
In conclusion, in this study with a whole proteomic microarray 17 peptides were 
found to be significantly cross-reactive with a monoclonal antibody p200-specific 
(Ab31) and two linear motifs were shared (“YSDF” and “YSNF). Among the 
targets, cross-reactivity was further studied for TG and GAK, for which reactivity 
was shown either at peptide and at the whole protein level with anti-p200 
monoclonal antibodies and with sera from mothers whose children have CHB. We 
propose that identification of reactivity to GAK or TG in sera of women with anti-
p200 antibodies may represent a subset of patients at risk to have a fetus 
developing CHB during pregnancy. Additional studies are needed to confirm the 
functional relevance of cross-reactivity to these proteins with the development of 
CHB and to better assess their association with the clinical outcome and severity 
of the disease. 
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FAMILY-BASED STUDY ON HLA 
ASSOCIATIONS WITH CHB 
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6. Materials and methods 
6.1 Study population 
Patients and their unaffected first-degree relatives were selected from the Swedish 
cohort (90) and from collaborating European study sites in Finland, Norway 
(Bergen) and Italy (Padua and Rome). All patients included in the study were 
diagnosed with third-degree CHB. In total 119 Swedish, 38 Finnish, 2 Norwegian 
and 14 Italian families, comprising 636 individuals (160 mothers, 136 fathers, 173 
cases and 167 unaffected siblings) were included. Detailed composition of families 
per Country is outlined in Table 4. For all families, maternal serum was available 
and was tested positive for anti-Ro52 antibodies (n=160). Further autoantibody 
profiling revealed n=127 (79.4%) mothers with anti-Ro60 and n=79 (49.4%) with 
anti-La antibodies. Amongst the 160 mothers 72 had a rheumatic diagnosis (24 
with SLE, 37 with Sjögren’s syndrome, 9 with undifferentiated connective tissue 
disease and 2 with other rheumatic disease), whereas for 88 there were no 
information available or no diagnosis of autoimmune disease. 
The study was approved by the Regional Ethical Committees in Stockholm, 
Helsinki, Bergen, Padua and Rome. Informed consent was given from all 
individuals (or their parents if individuals were <18 years) enrolled in the study. 
 
 
Cohort 
n Swedish Norwegian Finnish Italian Total 
n Families 119 2 38 14 173 
n Cases 119 2 38 14 173 
n Fathers 91 1 31 13 136 
n Mothers 109 1 37 13 160 
n Unaffected 
Siblings 
128 4 29 6 167 
Total 447 8 135 46 636 
Table 4. Description of composition and Country of origin of the families under investigation. 
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6.2 DNA preparation  
Erythrocytes were lysed in EDTA blood samples by adding Red Blood Cell Lysis 
Buffer (160 mmol/L NH4Cl, 10 mmol/L KHCO3, 50 mmol/L EDTA), and leucocytes 
collected by centrifugation at 1200 x g for 20 min at +4°C. Leucocytes were 
solubilized with 0.75% (w/v) SDS/ddH2O, and proteolytic digestion performed by 
adding 10 mg/mL Proteinase K (Invitrogen, Stockholm, Sweden) followed by 
overnight incubation at 37°C. Saturated NaCl (6M at a 1:3 ratio) was added, and 
precipitated proteins and lipid fractions spun down at 6000 x g for 10 min at room 
temperature. DNA was precipitated with 99% ethanol and dissolved in 1 x Tris-
EDTA buffer at 37°C. Photometric analysis of DNA concentration and purity was 
performed. DNA working solutions were diluted to a final concentration of 50 
µg/mL and stored at -80°C. 
6.3 HLA Imputation 
Low-resolution genotyping of DNA samples of the studied population was 
performed using the Illumina Human OmniExpress 950K chip. Briefly, after 
amplification of the whole genome, specific allele detection was performed in two 
steps, in which, BeadChip probes hybridized with single strand DNA in 
correspondence of a particular SNP and polymerase-dependent single base 
extension with labeled nucleotide gave specificity of the allele of the SNP (Figure 
27).  
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 HLA-A, -B, -Cw, -DPA1, -DPB1, -DQA1, -DQB1, -DRB1, -DRB3, -DRB4 and -
DRB5 genotyping was performed by imputation based on 5,636 tag SNPs from the 
chromosome 6 using the HLA*IMP:02 software 
(https://oxfordhla.well.ox.ac.uk/hla/), and an updated software version including 
Swedish reference genotypes. After quality control, alleles with >0.98 imputation 
quality measures were included in the analysis. Unaffected siblings' genotypes 
were used to infer parental alleles when such information was missing. High-
resolution genotyping of the HLA alleles significantly associated to CHB was, then, 
performed by DNA sequencing in order to identify specific sub-allele variants. 
 
6.4 Statistical analysis 
Statistical analyses in families were performed with the pedigree disequilibrium 
test (PDT) using Unphased (Version 3.0.13.) (187) selecting the "Full model" and 
"Test individual haplotypes" options for calculating transmission disequilibrium to 
cases, odds ratios (OR) and 95% confidence intervals (CI). P-values <0.05 were 
Figure 27. Workflow of the DNA genotyping performed with Illumina Human OmniExpress 950K 
chip. 
- 84 - 
 
considered significant and were further tested for statistical significance using 
Bonferroni correction. P-values denote deviation from 50% Mendelian 
transmission, whilst OR and CI calculations are based on risk allele frequencies in 
relation to all other allele frequencies as a reference and rely on the Unphased 
output of ratio between the estimated counts of a particular allele transmitted to 
cases and estimated number of the other alleles of the same gene transmitted to 
affected individuals. In particular, an OR>1 confers to a certain allele susceptibility 
to the disease outcome, whereas, if the OR<1 the allele is protective. 
Parental transmission frequency calculations were carried out using the parent-of-
origin tool in PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/). 
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7. Results 
7.1 Low resolution typed-HLA alleles associated with 
CHB 
In the HLA class I region, genetic analyses with Unphased and PLINK identified 
HLA-Cw*06 as a protective allele associated with CHB (p=0.003, OR=0.22, 95% 
CI 0.07 to 0.67, table 5). Notably, maternal HLA-Cw*06 alleles were significantly 
less transmitted to affected children (p=0.006) compared to paternal alleles (non-
significant), indicating that maternal regulatory effects in addition to the Cw*06 
allele transmission may contribute to the observed association. As for the HLA-B 
gene locus, it was found that HLA-B*50 significantly associated with CHB 
(p=0.046, table 5), however this finding was not verified after Bonferroni correction. 
Regarding HLA class II, HLA-DRB1*13 was associated with protection from CHB 
(p=0.007, OR=0.47 95% CI 0.24 to 0.91, table 6). Interestingly, HLA-DRB1*13 
parental transmissions were skewed with significantly fewer paternal transmission 
of the alleles to index cases (p=0.009). 
For the HLA-DQ genes, associations with CHB were found for both gene loci, 
namely HLA-DQA1 and DQB1. HLA-DQA1*01 and HLA-DQB1*06 were found to 
have a protective effect for CHB development (p=0.0016, OR=0.52, 95% CI 0.28 
to 0.95 and p=0.0036, OR=0.48, 95% CI 0.28 to 0.81, respectively, table 6), while 
HLA-DQA1*04 transmissions were associated with susceptibility (p=0.025, 
OR=1.25, 95% CI 0.56 to 2.79, table 6). Of note, paternal HLA-DQB1*06 allele 
transmissions were increased (p=0.038) while maternal transmissions did not 
deviate from the expected 0.5 transmission frequency, therefore suggesting an 
additional paternal influence in the reported protective effect. 
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None of the HLA-A, -DPA1, -DPB1, -DRB3, -DRB4, or -DRB5 alleles were 
significantly associated with CHB development (Supplementary Table 1).  
Gene*allele P-value 
Transmission 
frequency to cases OR 95% CI 
HLA-B     
*07 0.362 0.44   
*08 0.849 0.52   
*13 0.414 0.43   
*14 0.257 0.29   
*15 0.547 0.53   
*18 0.819 0.43   
*27 0.655 0.43   
*35 0.106 0.63   
*39 1 0.45   
*40 0.317 0.58   
*44 0.090 0.61   
*50 0.046 0 0 0 
*51 0.549 0.46   
*55 0.739 0.56   
*57 0.059 0.17   
Remaining alleles § 0.131 0.34   
HLA-Cw 
    *01 1 0.53 
*02 0.655 0.43 
*03 0.323 0.56 
*04 0.052 0.63 
*05 0.056 0.61 
*06 0.003 0.22 0.22 (0.07-0.67) 
*07 0.369 0.48 
*08 0.096 0.22 
*12 0.366 0.67 
*14 1 0.56 
*15 0.617 0.44 
*16 0.564 0.46 
*17 0.655 0.60 
*18 0.317 0 
 
 
 
 
Table 5. HLA-B and HLA-Cw allele association to CHB with corresponding p-value and parental 
transmission frequency to cases. OR and 95% CI are reported only for alleles with p-value<0.05. 
§ Alleles *37, *38, *41, *42, *45, *47, *48, *49, *52, *56 and *58 displayed low individual 
prevalence and were clustered together 
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Gene*allele P-value Transmission frequency to cases OR 95% CI 
HLA-DQA1          
*01 0.016 0.42 0.52 (0.28-0.95) 
*02 0.058 0.41   
*03 0.074 0.64   
*04 0.025 0.63 1.25 (0.56-2.79) 
*05 0.237 0.56   
*06 0.157 0     
HLA-DQB1          
*02 1 0.50   
*03 0.108 0.59   
*04 0.058 0.60   
*05 0.786 0.52   
*06 0.004 0.39 0.48 (0.28-0.81) 
HLA-DRB1          
*01 0.578 0.52   
*03 0.472 0.52   
*04 0.248 0.58 1.25 (0.66-2.37) 
*07 0.037 0.39 0.55 (0.27-1.14) 
*08 0.077 0.60   
*09 0.103 0.83   
*10 1 1   
*11 0.450 0.64   
*12 0.366 0.58   
*13 0.007 0.29 0.47 (0.24-0.91) 
*14 0.478 0.63   
*15 0.251 0.44   
*16 0.480 0.38     
 
 
 
 
 
 
Table 6. HLA-DQA1, -DQB1 and -DRB1 allele association to CHB with corresponding p-value and 
parental transmission frequency to cases. OR and 95% CI are reported only for alleles with p-
value<0.05. 
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7.2 High resolution typed-HLA allele variants 
associated with CHB  
To further investigate if particular HLA class II sub-alleles are associated with 
CHB, high resolution HLA-typing using the imputation method was performed. For 
the HLA-DQA1*01, we found DQA1*01:02 and DQA1*01:03 sub alleles 
protectively associated (p=0.043, OR=0.67, 95% CI 0.43 to 1.04 and p=0.019, 
OR=0.37, 95% CI 0.15 to 0.91, respectively, table 7) while HLA-DQA1*04:01 
associated with susceptibility for CHB (p=0.025, OR=1.60, 95% CI 0.82 to 3.10, 
table 7).  
As for the HLA-DQB1*06 allele, we found variants DQB1*06:03 and DQB1*06:04 
associated with CHB in a protective manner (p=0.033, OR=0.41, 95% CI 0.15 to 
1.09 and p=0.033, OR=0.43, 95% CI 0.16 to 1.14, table 7).  
Variant HLA-DRB1*13:01 was protectively associated with CHB development 
(p=0.0495, OR=0.45, 95% CI 0.17 to 1.23, table 7), while HLA-DRB1*13:02 and 
HLA-DRB1*13:03 became not significant (table 7). However, such analysis could 
not be performed for the rest of the significantly associated alleles since only HLA-
DRB1*07:01 and HLA-Cw*06:02 variants were found within the study population.  
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Gene*allele P-value 
Transmission 
Frequency to cases 
OR 95% CI 
HLA-DQA1          
*01:01 0.537 
  
  
*01:02 0.043 0.41 0.67 (0.43-1.04) 
*01:03 0.019 0.28 0.37 (0.15-0.91) 
*02 0.058 
  
  
*03 0.074 
  
  
*04:01 0.025 0.63 1.60 (0.82-3.1) 
*05 0.237 
  
  
*06 0.157       
HLA-DQB1          
*02 1 
  
  
*03:01 0.276 
  
  
*03:02 0.182 
  
  
*03:03 0.808 
  
  
*04:02 0.058 
  
  
*05 0.786 
  
  
*06:02 0.192 
  
  
*06:03 0.033 0.27 0.41 (0.15-1.09) 
*06:04 0.033 0.28 0.43 (0.16-1.14) 
*06:rest 0.655       
HLA-DRB1          
*01 0.578 
  
  
*03 0.473 
  
  
*04 0.248 
  
  
*07:01 0.037 0.39 0.55 (0.27-1.14) 
*08 0.077 
  
  
*09 0.102 
  
  
*10 1 
  
  
*11 0.450 
  
  
*12 0.366 
  
  
*13:01 0.0495 0.30 0.45 (0.17-1.23) 
*13:02 0.117 0.31 0.53 (0.22-1.25) 
*13:03 0.317 0.25 0.23 (0.02-2.44) 
*14 0.480 
  
  
*15 0.251 
  
  
*16 0.480       
 
 
 
Table 7. HLA-DQA1, -DQB1 and -DRB1 sub-allele variants association to CHB with 
corresponding p-value and parental transmission frequency to cases. OR and 95% CI are reported 
only for alleles with p-value<0.05. 
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7.3 Analysis of DRB1-DQA1-DQB1 haplotype in 
association with CHB  
Exploring the relationship of specific DRB1-DQA1-DQB1 haplotypes with the CHB 
family cohort under investigation, we performed a DRB1-DQA1-DQB1 haplotype 
association analysis with CHB development. In line with the single allele 
associations, we found the DRB1-DQA1-DQB1 13-01:03-06:03 haplotype 
significantly associated with protection from CHB development (p=0.025, 
OR=0.38, 95% CI 0.11 to 1.30, Supplementary Table 2). Moreover, haplotype 
DRB1-DQA1-DQB1 08-04:01-04:02 is significantly associated with CHB 
susceptibility (p=0.022, OR=1.55, 95% CI 0.58 to 4.20, Supplementary Table 2).  
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8. Discussion 
Transplacental transport of maternal anti-Ro52 autoantibodies is critical for CHB 
development. However, the low recurrence rate of CHB in subsequent gestations 
despite persistent maternal autoantibodies has turned researchers towards 
investigating the contribution of fetal factors in disease outcome. The strong link 
between the MHC locus and autoantibody mediated diseases provided the 
conceptual basis for a series of studies attempting to find genetic associations 
between CHB and specific alleles in the fetal MHC locus (143, 188). Emerging 
GWAS data (147) identified several polymorphisms within the MHC locus of 
children with cardiac manifestations of neonatal lupus associated with CHB 
development, substantiating influence of the fetal MHC locus in disease outcome. 
Additional in vivo findings further supported this notion by demonstrating that fetal 
MHC genetic constitution was a determining factor of CHB in a rat model (114). 
Meisgen et al recently identified novel susceptibility and protection conferring fetal 
alleles in the context of a transmission disequilibrium study in families with 3rd 
degree CHB cases (148). 
Herein, replication of these findings was sought in a cohort encompassing the 86 
Swedish families participating in the study by Meisgen et al. with the addition of 33 
Swedish, 2 Norwegian, 38 Finnish and 14 Italian families. Enrollment of families 
from different European countries would also help overcome limitations associated 
with regional effects (eg. environmental factors, population stratification) that could 
stochastically be mirrored in the calculated transmission frequencies and ensure 
that our findings reflect true genetic associations rather than casual findings 
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biased by regional confounders. Furthermore, additional associations with CHB 
outcome in the extended MHC locus complex were explored. 
In the genetic analyses, we corroborated previous findings that HLA-A allele 
transmission does not seem to play any significant role in disease outcome. In 
concordance with studies documenting a dominant effect of the HLA-Cw locus in 
CHB occurrence (144, 148), the HLA-Cw*06 allele was found to have a 
pronounced protective effect on disease outcome since allele transmission to 
affected children is significantly reduced. This finding appears in line with reports 
of the previous study. Notably, inclusion of more families added power to that 
finding as indicated by an even lower p-value in the present study (0.003 versus 
0.022 in the previous one).  
Numerous reports have linked specific HLA-DRB1 alleles with a variety of 
autoantibody induced diseases. Accordingly, we confirmed the strong protective 
effect conferred by DRB1*13 transmission. In line with this, decreased prevalence 
of DRB1*13 has been described in the context of several autoimmune diseases 
including anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic 
vasculitis (189) and a subtype of myasthenia gravis (190), as well as part of a 
protective haplotype for type 1 diabetes in an Iranian population (191). High 
resolution typing revealed that the variant conferring protection for CHB outcome 
was DRB1*13:01, whilst subtypes DRB1*13:02 and*13:03 were below the level of 
significance. On the contrary, HLA-DRB1*04 association with CHB was not 
confirmed in the expanded European cohort. This is potentially due to the fact that 
the addition of families with a different ancestry eliminated a population 
stratification effect that yielded the observed statistical significance in our previous 
study. 
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The present study further revealed a panel of novel genetic associations between 
HLA alleles and fetal susceptibility to CHB. Among them, HLA-B*50 allele 
transmission was observed to convey protection, however, low number of 
informative pedigrees for this specific allele (5 unaffected individuals, 0 cases) in 
conjunction with a marginally significant p-value decreased the power of this 
observation and does not allow for safe conclusions. Of note, HLA-B*50 has been 
additionally reported as a protection-conferring allele for Henoch-Schonlein 
purpura which is a common form of childhood vasculitis (192). 
Analysis of the MHC class II genetic region provided additional CHB associated 
alleles. HLA-DQA1*01 allele transmission was significantly decreased in children 
with CHB. High resolution typing singled out variants DQA1*01:02 and *01:03 
contributing to the observed protective effect. Only a few genetic analyses have 
associated these variants with autoimmune disease outcome so far. Interestingly, 
DQA1*01:02 was also under-represented in celiac disease children (193), 
suggesting a protective function of the variant in autoimmunity. Contrarly, allele 
DQA1*04:01 was more frequently transmitted to CHB affected fetuses. The only 
association observed within the DQB1 gene locus is the joint protection conferring 
effect of DQB1*06:03 and *06:04 allele variants. It is noteworthy that a similar 
protective effect is conveyed by these two allele variants also in type I diabetes 
mellitus in Arab populations (194). Similarly, HLA-DRB1*07 transmission 
frequency was also found to be significantly decreased in affected children (HLA-
DRB1*07:01 was the only observed variant in our cohort). Consistent with this 
observation HLA-DRB1*07 has also been reported to be significantly less frequent 
in patients with Grave’s disease (195) and multiple sclerosis in a meta-analysis 
study (196). 
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The association of specific DRB1-DQA1-DQB1 haplotypes with NLE (197) and 
several other autoimmune diseases (198-202) are long reported in the literature. 
This haplotype transmission was also investigated in this study and two DRB1-
DQA1-DQB1 haplotypes were identified to be significantly associated with CHB 
development. In particular, transmission of the haplotype DRB1*08-DQA1*04:01-
DQB1*04:02 was markedly increased in CHB patients predominantly reflecting the 
strong susceptibility conferring influence of DQA1*04:01 allele variant. On the 
contrary, DRB1*13-DQA1*01:03-DQB1*06:03 haplotype transmission was 
significantly decreased in CHB patients. Intriguingly, this haplotype was also 
demonstrated to convey protection in the context of Hashimoto thyroiditis (203). 
Coherently, all three alleles of this particular haplotype were found to confer 
protection in this study.  
Finally, our analysis revealed a parent-of-origin effect on transmission of CHB 
associated alleles. More specifically, maternal Cw*06 alleles were transmitted less 
frequently to affected children. Inversely, DQB1*06 and DRB1*07 displayed a 
markedly lower paternal transmission percentage than the respective maternal. 
Parent-of-origin influence has been suggested in the context of type 1 diabetes 
(204) and, more recently, for CHB, both in the human disease and in an animal 
model of the condition (114, 148). Such phenomena are considered to add an 
additional layer of epigenetic regulation in disease development. 
According to this findings, it would be tempting to envision a condition whereby 
MHC molecules encoded by these genes bind and present specific epitopes that 
promote the resolution of inflammatory phenomena in utero that would otherwise 
lead to irreversible 3rd degree block, as reviewed by Ambrosi et al. (139). We can 
alternatively hypothesize that the products of such protective alleles essentially 
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present antigenic epitopes that are not recognized by maternal pathogenic 
autoantibodies. Consistent with this hypothesis is the observation that haplotype 
DRB1*13-DQA1*01:03-DQB1*06:03 comprises genes encoding both α and β DQ 
polypeptidic chains, thereby influencing both subunits responsible for HLA-DQ 
molecules. However, in order to strengthen such claims the molecular pathways of 
specific antigen presentation need to be further elucidated. 
Taking into consideration that CHB can develop as fast as a single week following 
a normal echocardiographic examination, parental and/or fetal genotyping in anti-
Ro52-positive pregancies might be a useful tool to assess the risk of CHB in the 
fetuses in order to plan a proper management of the pregnancy, especially 
between the susceptible weeks 18th to 24th of gestation.  
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9. Supplementary data 
Gene*allele  P-value 
Transmission 
Frequency to cases 
OR 95% CI 
HLA-A          
*01 1 0.48 1 (1.00-1.00) 
*02 1 0.53 1.05 (0.64-1.73) 
*03 0.816 0.45 0.965 (0.54-1.74) 
*11 0.480 0.58 1.3 (0.59-2.86) 
*23 0.083 0.75 1.071e+008 (1.071e+008-1.071e+008) 
*24 0.480 0.25 0.814 (0.37-1.78) 
*25 0.564 0.75 1.88 (0.16-21.82) 
*26 0.467 0.42 0.811 (0.28-2.31) 
*29 0.317 0.33 0.502 (0.12-2.08) 
*30 1 0.56 1.077 (0.25-4.67) 
*31 0.564 0.42 0.733 (0.22-2.44) 
*32 0.439 0.60 1.513 (0.51-4.50) 
*33 1 0.25 0.878 (0.05-15.51) 
*68 0.602 0.53 1.234 (0.56-2.72) 
HLA-DPA1          
*01 0.906 
 
1 (1.00-1.00) 
*02 0.906   1.03 (0.65-1.64) 
HLA-DPB1          
*01 0.208 
 
1 (1-1) 
*02 0.777 
 
1.21 (0.55-2.65) 
*03 0.800 
 
1.24 (0.59-2.59) 
*04 0.652 
 
1.35 (0.74-2.46) 
*05 0.170 
 
2.76 (0.76-9.93) 
*09 0.157 
 
0 0 
*10 0.178 
 
5.00 (0.53-47.33) 
*11 0.564 
 
3.10 (0.20-47.07) 
*13 0.655 
 
1.58 (0.20-12.65) 
*14 0.706 
 
1.04 (0.21-5.11) 
*15 0.564 
 
2.36 (0.21-27.18) 
*16 0.564 
 
3.25 (0.22-48.78) 
*17 0.564 
 
2.45 (0.21-28.15) 
*19 1 
 
1.35 (0.08-23.02) 
*21 & *26 0.157   0 0 
HLA-DRB3          
*01 0.710 
 
1 (1-1) 
*02 0.345 
 
1.33 (0.73-2.41) 
*03 0.239 
 
0.67 (0.29-1.54) 
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N/A ¥ 0.801   1.08 (0.74-1.58) 
HLA-DRB4          
*01 1 
 
1 (1-1) 
N/A ¥ 1   1 (0.66-1.53) 
HLA-DRB5          
*01 0.210 
 
1 (1-1) 
*02 0.157 
 
0.42 (0.08-2.16) 
N/A ¥ 0.096   1.37 (0.87-2.17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1. HLA-A, DPA1, -DPB1, -DRB3, -DRB4 and –DRB5 allele association to 
CHB with corresponding p-value, parental transmission frequency to cases, OR and 95% CI. To 
note, none of these alleles are reached significance. 
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DRB1-DQA1-DQB1 
Haplotype 
P-value OR 95% CI 
01-01:01-05 0.578     
03-04-04:02 0.317 
 
  
03-05-02 0.531 
 
  
04-03-03:01 0.439 
 
  
04-03-03:02 0.237 
 
  
04-03-04:02 0.157 
 
  
07-02-02 0.131 
 
  
07-02-03:02 1 
 
  
07-02-03:03 0.058 
 
  
08-04:01-04:02 0.022 1.55 (0.58-4.20) 
08-06-03:01 0.317 
 
  
08-06-04:02 0.317 
 
  
09-03-03:03 0.103 
 
  
10-01:01-05 1 
 
  
11-01:03-03:01 0.317 
 
  
11-05-03:01 0.336 
 
  
12-05-03:01 0.366 
 
  
13-01:02-06:03 0.317 
 
  
13-01:02-06:04 0.074 
 
  
13-01:02-06:rest 0.564 
 
  
13-01:03-06:02 1 
 
  
13-01:03-06:03 0.025 0.38 (0.11-1.3) 
13-01:03-06:04 0.157 
 
  
13-05-03:01 0.564 
 
  
14-01:01-05 0.480 
 
  
15-01:02-05 0.564 
 
  
15-01:02-06:02 0.232 
 
  
15-01:02-06:03 0.317 
 
  
15-01:03-03:02 0.317 
 
  
15-01:03-06:rest 1 
 
  
15-03-05 0.317 
 
  
16-01:02-05 0.480     
 
 
 
 
Supplementary Table 2. DRB1-DQA1-DQB1 haplotype association analysis with CHB 
development. Each combination of alleles analyzed is reported with the correspondent p-value and 
OR and 95% CI if the haplotype reached significance. 
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10. Conclusions 
The molecular mechanisms underlying CHB are yet unclear. Several genetic and 
enviromental risk factors are emerging as associated with the disease, making it 
difficult to generate an overall picture considering the complexity of this 
autoimmune disease. With the current thesis, we focused, firstly, on understanding 
more about the pathogenic mechanism leading to CHB by the identification of 
cross-reactive targets of anti-Ro52 antibodies. Secondly, we investigated genetic 
associations in the MHC locus to CHB in an European cohort of families in which 
children with CHB were born.  
In the first part of the thesis, we found two linear epitopes shared by 17 cross-
reactive peptides, and we confirmed cross-reactivity of anti-Ro52/p200 antibodies 
to GAK and TG. Notably, hypotyroidism in anti-Ro52-positive women has been 
associated with the development of CHB (152). Our findings suggest that there is 
a link between reactivity to TG in anti-p200-positive sera and hypotyroidism with 
CHB. In order to understand this connection clearly, more studies are necessary. 
Secondly, GAK, the second cross-reactive target, shares high homology with 
DNAJC6/Auxilin, which has recently been indicated as a novel fetal susceptibility 
gene for CHB as well as being functionally associated with CHB (149). Both these 
two proteins are involved in the clathrin-dependent trafficing of vesicles in the cell, 
revealing that this pathway might be involved in the development of the disease.  
In the second part of the thesis, our genetic analysis identified HLA-Cw*06,            
-DRB1*13, -DQA1*01 and -DQB1*06 as protective alleles for CHB, while HLA-
DQA1*04 transmission was associated with susceptibility to the disease. These 
alleles encode specific isoforms of the MHC receptors expressed intracellularily    
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(-Cw*06), or on the surface of dendritic cells, macrophages as well as B- and T-
lymphocytes (-DRB1*13, -DQA1*01, -DQB1*06 and -DQA1*04), which are 
responsible for presenting specific epitopes for activation or resolution of an 
immune response.  
Taking the findings of both studies into consideration, one may visualize a 
situation where the fetal HLA genes modulate the inflammatory response following 
the exposure to anti-Ro/SSA antibodies. In particular, MHC molecules encoded by 
the protective alleles could bind and present specific epitopes that promote the 
resolution of inflammation that would otherwise lead to irreversible atrioventricular 
block, as reviewed by Ambrosi et al. (139). Alternatively, the products of such 
protective alleles could present antigenic epitopes that are not recognized by 
maternal pathogenic autoantibodies. Fetal MHC proteins that confer susceptibility, 
on the other hand, could have a specific conformation of the epitope recognition 
site that enables the binding of sequences that are cross-reactive with maternal 
anti-Ro52 antibodies, allowing the initiation of an immune response which may 
lead to CHB. According to this hypothesis, cross-reactivity of maternal anti-Ro52 
antibodies would be correlated with the fetal MHC protective or susceptibility-
conferring allele repertoire. A recent study provided molecular evidence of cross-
reactivity of anti-citrullinated antibody (ACPA) to citrullinated vinculin epitopes 
presented by the predisposing HLA-DQ5, -DQ7.3 and -DQ8 haplotypes in RA 
(205), showing an interplay between HLA haplotype and a cross-reactive 
autoimmune response.  
In conclusion, CHB is emerging as a complex autoimmune disease where 
maternal anti-Ro/SSA and/or anti-La/SSB antibodies are necessary but not 
sufficient for the onset of the disease. CHB may develop in fetuses with a specific 
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MHC genetic background, potenitally favorable for the production and exposition 
of epitopes that are cross-reactive with anti-Ro52 antibodies. Enviromental and 
maternal factors, like age, hypothyroidism, low vitamin D levels, gestational 
susceptibility weeks occurring during the winter season as well as infections during 
pregnancy may interplay in the development of the condition and affect the clinical 
outcome and the severity of the disease in the fetus (Figure 28). 
 
 
  
Figure 28. Schematic pictures of the factors involved in the development of CHB. 
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Preciso e meticoloso, attento al dettaglio 
Madre lingua Italiano 
Autovalutazione  Comprensione Parlato Scritto 
Livello europeo (*)  Ascolto Lettura Interazione orale Produzione 
orale 
 
Inglese  C1 C1 C2 C1 C1 
Spagnolo  B1 A2 A2 A1 A1 
Svedese  A1 A1 A1 A1 A1 
 (*)  Quadro comune europeo di riferimento per le lingue  
Patente automobilistica (Patente B) 
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14. Attivita' svolte nel triennio di dottorato 
I anno 
Durante il primo anno di dottorato la mia attività di ricerca è cominciata con una 
collaborazione con la mia collega dott.ssa Elena Mattia nel progetto di confronto tra le 
performance di un saggio immunoenzimatico basato sulla chemiluminescenza (CLIA) e 
quella di un ELISA home made per la determinazione degli anticorpi anticardiolipina (aCL) 
IgG/IgM e anti-β2 Glicoproteina I (anti-β2GPI) IgG/IgM in una coorte di pazienti affetti da 
APS primaria ed in un gruppo di pazienti sieronegativi per valutarne il valore diagnostico. 
Concomitantemente a tale attività, d’accordo con la mia tutor, prof.ssa Amelia Ruffatti, 
sono stati presi contatti con la prof.ssa Marie Wahren-Herlenius del Karolinska Institutet 
(KI, Stoccolma, Svezia) per un mio soggiorno presso il suo laboratorio da effettuare nella 
seconda metà del dottorato per lavorare su un progetto di ricerca riguardante la 
suscettibilità genetica associata al congenital heart block. (CHB). Per tale collaborazione 
ho individuato le famiglie in cui si sono nati bambini con CHB. Dopo l’arruolamento, 
campioni di siero e di DNA, inseme alle informazioni cliniche, sono stati inviati al 
laboratorio della prof.ssa Wahren-Herlenius. 
Nell’arco di quest’anno ho partecipato ai “Meetings di Reumatologia 2013. XXXVII 
edizione” organizzati dal coordinatore di indirizzo; al “9th Meeting of the European Forum 
on Antiphospholipid Antibodies” a Cracovia (Polonia) con contributo scientifico (poster), 
alla “Summer school” scuole/corsi di dottorato di ricerca dell’area medica, allo STEPS 
2013 Seminars Towards Enterprise for PhD Students organizzato dalla Confindustria di 
Padova, al 50° Congresso Nazionale SIR con contributo scientifico a Napoli (poster) e al 
4th Symposium “Autoinflammatory day”. 
 
II anno 
Nel corso del secondo anno, ho continuato raccolta di campioni di siero e di DNA dalle 
famiglie con figli affetti da CHB. Il 2 Giugno 2014 ho iniziato la mia attività di ricerca 
presso il KI. Qui, ho iniziato un progetto rivolto all’identificazione di target di cross-
reattività degli anticorpi anti-Ro52/p200 associati al CHB attraverso uno screening su 
base proteomica attraverso un anticorpo monoclonale specifico per la regione p200. Una 
volta identificati gli epitopi di cross-reattività, ulteriori esperimenti hanno confermato cross-
reattività con anticorpi monoclonali e con sieri di pazienti verso le proteine Tiroglobulina e 
GAK (Cyclin G-Associated Kinase). Nell’arco di quest’anno ho partecipato ad un corso di 
Inglese Accademico di 30 ore di livello B2-C1 per dottorandi presso l’Università degli Studi 
di Padova. Ho partecipato, inoltre, ai “Meetings di Reumatologia 2014. XXXVIII edizione” 
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organizzati dal coordinatore di indirizzo; al Convegno “Joint Meeting Padova – 
Strasburgo”, Palazzo Bo al “9th International Congress on Autoimmunity” a Nizza 
(Francia) con contributo scientifico (comunicazione orale), al 51° Congresso Nazionale 
SIR con contributo scientifico a Rimini (poster e comunicazione orale). In Svezia ho 
partecipato all’Inflammation Day 2014” e al Nobel Symposium “Renaissance in diagnosis 
of monogenic diseases” presso il KI a Stoccolma (Svezia). Ho partecipato inoltre alla 
Nobel lecture dei vincitori del premio Nobel per la Medicina e Fisiologia presso il 
Karolinska Institutet a Stoccolma (Svezia).  
 
III anno 
Nel corso di quest’anno ho continuato la permanenza presso il KI, portando avanti la 
ricerca riguardante l’identificazione dei target di cross-reattività degli anticorpi anti-
Ro52/p200. Contemporaneamente, ho iniziato un secondo progetto multi-centrico volto a 
studiare l’associazione genetica del locus Human Leucocyte Antigen (HLA) con il CHB. 
L’analisi genetica è stata condotta in una coorte di famiglie Europee in cui sono nati 
bambini con CHB con lo scopo di identificare quali alleli del locus HLA sono trasmessi dai 
genitori ai figli con CHB con una frequenza che si discosta significativamente dalla 
frequenza del 50% in accordo alle leggi di Mendel sulla segregazione indipendente dei 
caratteri. Oltre a tale progetto, ho partecipando, collaborando ad uno studio di 
caratterizzazione funzionale di una famiglia genica associata geneticamente alla 
Sindrome di Sjogren. In particolare, mi sono occupato dello studio di espressione genica 
di tali geni in un set di 14 organi provenienti da 10 topi wildtype. Tale lavoro, però, non è 
parte della mia tesi. 
Nel corso di quest’anno ho partecipato al “KiiM (Karolinska Inflammation and Immunology 
network) retreat”, Stoccolma (Svezia) con contributo scientifico (poster).  
Il 18 Dicembre 2015 ho concluso il mio soggiorno di ricerca presso il KI e sono tornato a 
Padova. 
 
